1	Higher dietary micronutrients are required to maintain optimal
2	performance of Atlantic salmon (Salmo salar) fed a high plant material
3	diet during the full production cycle
4	
5	Luisa M. Vera <sup>1</sup> , Kristin Hamre <sup>2</sup> , Marit Espe <sup>2</sup> , Gro-Ingunn Hemre <sup>2</sup> , Kaja Skjærven <sup>2</sup> ,
6	Erik-Jan Lock <sup>2</sup> , Antony Jesu Prabhu <sup>2</sup> , Daniel Leeming <sup>3</sup> , Herve Migaud <sup>1</sup> , Douglas R.
7	Tocher <sup>1</sup> , John F. Taylor <sup>1</sup> *
8	
9	<sup>1</sup> Institute of Aquaculture, School of Natural Sciences, University of Stirling, Stirling, UK
10	<sup>2</sup> Institute of Marine Research, Nordnes, 5817 Bergen, Norway
11	<sup>3</sup> BioMar Ltd., North Shore Road, Grangemouth FK9 8UL, Scotland, UK
12	
13	*Correspondence: E-mail: j.f.taylor@stir.ac.uk (J. Taylor)
14	Tel: 00-44-01786 467929
15	

Accepted refereed manuscript of: Vera LM, Hamre K, Espe M, Hemre G, Skjærven K, Lock E, Prabhu AJ, Leeming D, Migaud H, Tocher DR & Taylor JF (2020) Higher dietary micronutrients are required to maintain optimal performance of Atlantic salmon (Salmo salar) fed a high plant material diet during the full production cycle. *Aquaculture*, 528, Art. No.: 735551. https://doi.org/10.1016/j.aquaculture.2020.735551 © 2020, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/

# 16 Abstract

17 A full life cycle (parr to harvest) study of growth and performance was conducted in Atlantic salmon 18 fed diets high in plant ingredients supplemented with graded levels of a nutrient premix (NP), 19 containing selected amino acids, taurine, cholesterol, vitamins and minerals to re-evaluate current 20 nutrient recommendations. Triplicate groups were fed one of three NP levels included at 1x, 2x and 4x, where 1x corresponds to recommendations of NRC (2011). Whole body and specific tissue 21 22 concentrations of nutrients were monitored throughout the experiment as requirement markers. 23 Growth in parr was significantly enhanced in 2xNP, but restricted in 4xNP, while in post-smolts 24 growth was positively correlated with NP level. Spinal deformity decreased linearly with increased 25 NP level in both smolt and post-smolts. When fishmeal and fish oil are present at very low levels, as in the present study, we found beneficial effects with moderate increased levels of the B-vitamins 26 27 niacin, riboflavin and cobalamin. Further, vitamin C should be increased, based on metabolic 28 responses, although it did not influence growth. Increased Zn and Se affected fish metabolism in a 29 positive manner. Alterations in hepatic transcriptome profiles and expression of specific genes of 30 metabolic pathways were evident in response to micronutrient supplementation level. Collectively, 31 increasing the levels of the micro-nutrient package to a too high level, showed a negative effect and 32 cannot be recommended. NRC (2011) recommendations should therefore be revised for diets in which 33 plant ingredients form the major part of the formulation.

34

Keywords: Fishmeal, fish oil, plant proteins, vegetable oil, vitamins, minerals, skeletal deformity,
sustainable feeds.

# 37 1. Introduction

Over the last decade and a half, feed formulations for farmed Atlantic salmon (Salmo salar) have 38 39 changed with marine raw materials, fish oil (FO) and fishmeal (FM), being increasingly replaced by 40 high levels of plant ingredients (Gatlin III et al., 2007; Hardy, 2010; Turchini et al., 2011). Levels of 41 marine ingredients, FM and FO, in salmon feeds are now approximately 20 % of total feed inclusion 42 compared with 90 % around 20 years ago (Ytrestøyl et al., 2015). Over this period, many studies 43 investigated the effects of the inclusion of plant-derived ingredients in feeds. The majority of studies 44 focussed on the impacts on growth performance and feed utilisation (Torstensen et al., 2000; Opstvedt 45 et al., 2003; Mundheim et al., 2004; Espe et al., 2006; Torstensen et al., 2005; Pratoomyot et al., 2008; 46 Waagbø et al., 2013), and also on product quality for human consumers (Waagbø et al., 1993; 47 Mundheim et al., 2004; Torstensen et al., 2005; Menovo et al., 2007). However, overall, the development and application of modern, plant-based feed formulations has been largely successful 48 49 enabling salmon production to be maintained and/or increased despite the finite and limited supplies 50 of FM and FO (Shepherd & Jackson, 2013).

51 Despite the above, formulating salmon feeds with high levels of plant meals and vegetable 52 oils significantly affects a range of nutrients (Sissener et al., 2013), including changing micronutrient concentrations and their chemical forms, as well as introducing compounds that interact with 53 54 micronutrient uptake and metabolism (Olsvik et al., 2013). Importantly, in addition to affecting fish 55 growth, feed efficiency and product quality, these changes in nutrient composition could also affect 56 fish health and welfare (Oxley et al., 2005; Seierstad et al., 2005; Waagbø, 2006; Hemre & Sandnes, 57 2008; Waagbø, 2008; Seierstad et al., 2009). As a result, there has been increasing interest in improving knowledge of practical nutrient requirements of Atlantic salmon when fed modern, plant 58 59 based feeds (Hansen et al., 2015). In particular, there has been a focus on micronutrients (minerals, 60 vitamins etc.) as it is believed that these were likely supplied in surplus in feeds containing high levels 61 of FM and FO, and that levels of some micronutrients in terrestrial raw materials can be lower 62 (Sissener et al., 2013). When feeding plant-based diets enriched with the micronutrients folate,

vitamin B12, vitamin B6, methionine and choline to zebrafish (*Danio rerio*) over the entire life cycle, fish responded with increased growth, higher fecundity and altered metabolic profile of several Nmetabolites, indicating an overall positive effect of a micronutrient-enriched plant-based diet (Skjaerven et al., 2016). As a consequence, micronutrient and mineral requirements need careful reevaluation when substituting raw materials, as the current established micronutrient supplements / premixes (National Research Council, NRC 2011) may not be sufficient to satisfy requirements for Atlantic salmon, especially throughout the whole life cycle.

To investigate this, micronutrient requirements of Atlantic salmon fed diets formulated with 70 71 high levels of plant meals and vegetable oil were studied in two regression experiments in parr in 72 freshwater and post-smolts in seawater (Hamre et al., 2016; Hemre et al., 2016; Prabhu et al. 2019a). A nutrient package, consisting of vitamins B, C, D<sub>3</sub>, E, minerals, cholesterol, taurine and histidine 73 74 was fed at various levels from below NRC (2011) recommended levels to well above NRC levels. 75 Growth, health and welfare parameters responded to nutrient packages in parr, but not to the same extent in post-smolts (Hemre et al., 2016). Thus, parr fed diets containing the nutrient package 76 77 supplying micronutrients above NRC (2011) recommended levels showed improved protein retention, 78 and reduced liver and viscera indices, whereas the response was less pronounced in post-smolt 79 (Hemre et al., 2016). Significant regressions were obtained in body compartments for vitamin C and 80 several of the B-vitamins and, based on these results, the authors recommended that B-vitamin 81 supplements should be adjusted in plant-based diets for Atlantic salmon (Hamre et al., 2016; Hemre 82 et al., 2016). There were no indications of vitamin E deficiency when vitamin E was not supplemented, 83 indicating that the ingredients delivered sufficient amounts of vitamin E. Nevertheless, it was recommended to supplement 150 mg kg<sup>-1</sup>vitamin E to compensate in periods of oxidative stress 84 85 (Hamre et al., 2016). Regarding the micro-minerals, requirements of Atlantic salmon fed the plantbased diet were met at NP inclusion of 100-150 % and 150-200 % in parr and post-smolt, respectively 86 87 (Prabhu et al., 2019a).

88 More recently, the impact of micronutrients was investigated in both diploid and triploid 89 Atlantic salmon parr fed graded levels of a nutrient package (NP) from around 30 g to seawater 90 transfer (Taylor et al., 2019). The diets were formulated with very low levels of marine ingredients 91 and supplemented with three levels of NP (L1, 100 %; L2, 200 % and L3, 400 % NP), which contained 92 24 micronutrients including selected amino acids, vitamins, minerals, taurine and cholesterol. The 93 NP was based on the minimum nutrient recommendations for Atlantic salmon (NRC, 2011). Diploid 94 parr fed L2 showed significantly improved growth and reduced liver (HSI) and viscera (VSI) indices, 95 and hepatic steatosis, compared to fish fed L1, while diploids fed L3 also showed improved growth 96 in the first 14 weeks, although growth rate was subsequently reduced (Taylor et al., 2019). In contrast, 97 dietary NP level had less effect on triploid growth rate, VSI or HSI, and smoltification was not 98 affected by NP in either ploidy. Overall, results suggested that, while micromineral requirements 99 were met, other micronutrients may require to be supplemented above current NRC (2011) 100 recommendations for optimal growth and liver function of diploid Atlantic salmon fed plant-based 101 diets in freshwater (Taylor et al., 2019). In addition, the above study also investigated the impact of 102 NP level on skeletal deformity and bone health including the prevalence, localisation and pathology 103 of spinal malformation, and vertebral expression of bone biomarker genes (Vera et al., 2019). This 104 study showed that prevalence of radiologically detectable spinal deformities decreased with 105 increasing micronutrient supplementation when fed from parr to smolt. Concomitantly, expression of 106 many osteogenic genes (bone morphogenic protein, osteocalcin, alkaline phosphatase, matrix 107 metallopeptidase, insulin-like growth factor) increased with increasing NP inclusion. The 108 observations suggested that components thereof, or interactions between micronutrients within the 109 NP may be affecting downstream processes involved in bone formation and remodelling, which also 110 occur through active epigenetic regulatory mechanisms of gene expression (Saito et al., *unpublished* 111 data).

112 The previous trials investigating dietary micronutrients in salmon were all carried out during 113 the freshwater phase other than one short-term (5-month) trial in post-smolt in seawater (Hamre et al., 2016; Hemre *et al.*, 2016; Taylor et al., 2019; Vera et al., 2019; Prabhu, et al., 2019a). Therefore,
the aim of the present study was to determine the influence of micronutrients in Atlantic salmon fed
diets formulated with very low levels of marine ingredients over the entire life cycle. To this end,
diploid Atlantic salmon were fed from around 30 g to 3 Kg with plant-based feeds supplemented with
the same NP as described above to produce three experimental diets (L1, 100 %; L2, 200 % and L3,
400 % NP). The impacts of NP levels on growth, feed efficiency, nutrient retention, skeletal
development and liver gene expression were determined.

121

#### 122 2. Methods & Materials

# **2.1 Fish and feeds**

The trial was carried out with Atlantic salmon obtained from SalmoBreed AS (Norway). All experimental procedures and husbandry practices were conducted in compliance with the Animals Scientific Procedures Act 1986 (Home Office Code of Practice) in accordance with EU regulation (EC Directive 86/609/EEC) and approved by the Animal Welfare and Ethical Review Board (AWERB) of the University of Stirling. All fish were monitored daily by the Named Animal Care and Welfare Officer (NACWO).

130 Feeds were formulated to reflect standard practice in commercial salmon feeds in terms of 131 protein, oil and energy contents. Thus, feeds were initially formulated to contain 48 % protein and 132 20 % lipid (~22 MJ), with protein content decreasing and lipid content increasing with increasing pellet size to reach 36 % protein and 34 % lipid (~24 MJ) in the largest pellet size in seawater. The 133 134 experimental feeds were a low FM/FO formulation (initially 15 % and 8 % in freshwater, decreasing 135 to 5% and 3 % respectively in seawater, Tables 1 & 2). Feeds were supplemented with a nutrient 136 package (NP, Tables 3 and 4) at one of three inclusion levels to produce 3 dietary treatments: L1, 137 100 % NP; L2, 200 % NP; L3, 400 % NP (Table 4), the assumption being that the 100 % NP package should contain 100 % of assumed requirement based on the levels reported for Atlantic salmon at the 138 139 time (NRC, 2011). Specifically, the NP contained 24 nutrients in total these being; vitamins (A, D3,

E, K3, C, thiamine, riboflavin, B6, B12, niacin, pantothenic acid, folic acid and biotin), minerals (Ca, Co, I, Se, Fe, Mn, Cu and Zn), crystalline amino acids (L-histidine and taurine) and cholesterol. Total and available phosphorus were fixed in all diets at 12.0 and 9.0 g kg<sup>-1</sup> respectively, and magnesium at 1.5 g kg<sup>-1</sup>, and were not part of the NP. Pellet size (2 mm, 3.5 mm, 5 mm, 7 mm, 9 mm) was adjusted according to fish weight. All non-oil ingredients were mixed and pellets produced by extrusion to produce three base pellets that had oil added by vacuum coating. All feeds were produced at the BioMar Tech-Centre (Brande, Denmark).

147

# 148 **2.2 Feeding trial**

149 The freshwater phase was carried out at the Niall Bromage Freshwater Research Facility (Stirlingshire, 150 UK). Initially, 500 diploid salmon pre-smolt (initial mean weight,  $38.2 \pm 0.6$  g) were stocked (2 Sept-151 14) into nine x 1.6 m<sup>3</sup> circular fibreglass tanks (3 tanks / diet, initial stocking density  $12.0 \pm 0.1$  kg 152 m<sup>-3</sup>). Fish were acclimated to the experimental tanks for 2 weeks (Fed BioMar Inico Plus) before 153 being fed the experimental diets. Fish were fed continuously during the light period of the light:dark 154 cycle by automatic feeders (Arvotec T2000, Arvotec, Finland) controlled by a PC system. Specific 155 feeding rates (SFR; % tank biomass per day) were adjusted automatically according to predicted 156 growth and daily temperature. An out-of-season photoperiod (LL - 400 °days LD14:10 - 400 °days 157 LL) and ambient water temperature (12 - 16 °C) was applied to produce S0+ smolts (final stocking density 20.2 - 22.8 kg m<sup>-3</sup>), with lighting provided by two 28 W fluorescent daylight bulbs (4000 °K; 158 159 RS Components, UK) mounted centrally within the tank lid. Water was supplied by an upstream 160 reservoir under flow-through conditions (10 L min<sup>-1</sup>). Oxygen levels were always higher than 8 mg 161  $L^{-1}$ . Uneaten feed recovery was not feasible during the freshwater phase.

162 Smolts were transferred (4 Nov-14) to the Marine Harvest (Mowi) Feed Trial Unit (Ardnish, 163 Scotland) and on-grown for 11 months in nine 5x5x5 m sea pens under natural photoperiod and 164 ambient water temperatures ranging from 6 to 16 °C. Triplicate groups of 250 post-smolts from 165 respective tanks were stocked per pen (Initial stocking density 0.17 - 0.19 kg m<sup>-3</sup>) and on-grown to a final size of ~2.5 Kg (15 Sept-15, Final stocking density 4.52 – 5.18 kg m<sup>-3</sup>). Fish were fed
continuously during daylight by automatic feeders (Arvotec T2000) controlled by a PC system.
Specific feeding rates (SFR; % pen biomass per day) were adjusted weekly according to predicted
growth and water temperature. Waste feed was collected per pen by means of air uplifts following
meal delivery ensuring satiation and allowing calculation of total daily feed intake.

171

# 172 **2.3 Growth and feed efficiency**

173 Fish were sampled at start and end of the freshwater phase, and then at approximately 250 g, 500 g, 174 1 kg, and ~2.5 kg in seawater prior to dietary pellet size/formulation changes. In freshwater at each 175 sampling point, 50 fish / tank were anaesthetised (50ppm Tricaine, PHARMAO, UK), individual 176 weights  $(\pm 0.1 \text{ g})$  and fork lengths  $(\pm 1.0 \text{ mm})$  measured, while in seawater, all fish per pen were 177 counted and individually measured. Following measurement, all fish were allowed to recover in 178 aerated water before returning to their original experimental tanks/pens. Fulton's condition factor (K) 179 was calculated using:  $K = (WL^{-3})100$ ; where W is body weight (g) and L is fork length (mm). Weight 180 data were used to calculate specific growth rate (SGRwt), thermal growth coefficient (TGC) and feed 181 conversion rate (FCR) for each sampling period where SGRwt was calculated as:  $(e^{g^{-1}}) \times 100$ , where  $g = (\ln(W_f) - \ln(W_i)) \times (t_2 - t_1)^{-1}$  and TGC was calculated as:  $(W_{f1/3} - W_{i1/3}) \times (\sum D_o) - 1$ , where  $W_f$  is the 182 183 final body weight,  $W_i$  is the initial body weight and  $D_0$  is the cumulative sum of water temperature in 184 degrees per day. FCR was calculated as: Fi /  $(B_f - B_i + B_m)$  where F<sub>i</sub> is the fed intake (kg), B<sub>f</sub> is the final 185 biomass (kg),  $B_i$  is the initial biomass (kg) and  $B_m$  is the mortality biomass for the period (kg). 186 Maturation at harvest was determined by assessment of external appearance of secondary sexual 187 characteristics and gonad development (n = 30 / pen), where gonadosomatic-index (GSI) was 188 calculated as GSI (%) =  $(G_W \times 100)/B_W$ . Fish were classified as sexually recruited based on a threshold 189 value of GSI >0.20 % or >1.0 % for males and females respectively (Kadri et al., 1997).

190

# 191 **2.4 Biochemical composition and nutrient retention**

At the termination of the trial, 10 fish per pen (30 / diet) were euthanised using lethal anaesthesia (>200 mg L<sup>-1</sup> Tricaine, PHARMAQ UK) to provide samples for biochemical analyses. Five whole fish per pen (15 / diet, in 3 pen pools, n = 3) were taken for the determination of proximate composition (MOPA), minerals, and fatty acid composition. In addition, muscle/flesh (Norwegian Quality Cut, NQC) were collected from 5 additional fish per pen (15 fish/diet in 3 pen pools, n = 3) for MOPA, minerals, carotenoid (flesh), fatty acid composition, and total amino acid.

198

# 199 2.4.1. Proximate composition

Whole fish and diets were ground before determination of proximate composition according to standard procedures (AOAC, 2000). Five fish were pooled per pen and three technical replicates for the single batch feeds were analysed. Moisture contents were obtained after drying in an oven at 110 °C for 24 h and ash content determined after incineration at 600 °C for 16 h. Crude protein content was measured by determining nitrogen content (N x 6.25) using automated Kjeldahl analysis (Tecator Kjeltec Auto 1030 analyzer, Foss, Warrington, UK) and crude lipid content determined gravimetrically after Soxhlet lipid extraction (Tecator Soxtec system 2050 Auto Extraction apparatus).

# 208 2.4.2. Amino acid, mineral and vitamin analyses

209 Free amino acids and nitrogen metabolites were analysed using the Biochrome with post-column 210 derivatisation with ninhydrin as described by Espe et al. (2014). The total amino acids in whole body 211 and diets were analysed after being hydrolysed in 6N HCl for 22 h as previously described (Espe et 212 al., 2014) and used for calculation of amino acid retention (% deposited of consumed amino acid). 213 The B-vitamins biotin, niacin, folate, pantothenic acid and cobalamin were all determined by 214 microbiological methods as described in detail previously (Mæland et al., 2000; Feldsine et al., 2002). 215 Some of the B-vitamins were determined by HPLC by standard methods; thiamine (CEN, 2003), 216 vitamin B6 (CEN, 2006) and riboflavin (Brønstad et al., 2002). Multi-element determination was 217 done by ICP-MS (inductively coupled plasma mass spectrometry) (Julshamn et al., 1999). HPLC was 218 used for determination of ascorbic acid (Mæland and Waagbø, 1999) and tocopherols were analysed 219 according to standard methodology (CEN, 1999). Vitamins A and D were analysed according to 220 Moren et al. (2004) and Horvli and Lie (1994), respectively.

- 221
- 222

# 2.4.4. Lipid content and fatty acid composition

223 Samples of whole bodies and NQC from five fish per tank were prepared as pooled pen homogenates 224 (n = 3 per diet). Total lipid was extracted from approximately 1 g of sample by homogenising in 225 chloroform/methanol (2:1, v/v) using an Ultra-Turrax tissue disrupter (Fisher Scientific, 226 Loughborough, UK), and content determined gravimetrically (Folch et al., 1957). Fatty acid methyl 227 esters (FAME) were prepared from total lipid by acid-catalysed transesterification at 50 °C for 16 h 228 (Christie, 2003), and FAME extracted and purified as described previously (Tocher and Harvie, 1988). 229 FAME were separated and quantified by gas-liquid chromatography using a Fisons GC-8160 230 (Thermo Scientific, Milan, Italy) equipped with a 30 m  $\times$  0.32 mm i.d.  $\times$  0.25 µm ZB-wax column 231 (Phenomenex, Cheshire, UK), on-column injector and a flame ionisation detector. Data were 232 collected and processed using Chromcard for Windows (version 2.01; Thermoquest Italia S.p. A., 233 Milan, Italy). Individual FAME were identified by comparison to known standards and published 234 data (Tocher and Harvie, 1988).

235

#### 236 2.4.5. Pigment analysis

237 Flesh carotenoid levels were determined using a modified version of the JX Nippon Oil Corporation's 238 Analytical methods for Panaferd-AX. Briefly, three grams of homogenised flesh samples were 239 transferred to a 50 ml Ouickfit tube. Measurements of the samples were done to two decimal places. 240 One mL of deionised water was added to the tubes. Subsequently, 5 ml of tetrahydrofuran 241 (THF)/methanol (20:1, v/v) were added and the mixture shaken vigorously for 1 min and then mixed 242 using a shaker for 5 min. Ten millilitres of iso-hexane were then added and the contents mixed 243 thoroughly before being centrifuged at 340 g for 10 min. The supernatant was transferred to a 50 ml 244 volumetric flask. Five mL of tetrahydrofuran (THF)/methanol (20:1, v/v) were added to the initial 245 tube and the process repeated three times, making a pool of four extractions in the volumetric flask. 246 Then, iso-hexane/THF/methanol (40:20:1, v/v/v) was added to the flask making up the volume of the 247 pooled extractions to 50 ml. Subsequently, 10 ml of the samples were removed and evaporated to 248 dryness under a nitrogen stream at room temperature, before being re-suspended in 2 ml isohexane 249 prior to HPLC analysis. Samples were injected on a Thermo Scientific Ultimate 300 HPLC system 250 equipped with a 150 x 4.6 mm 3µ Phenomenex silica column with detection at a wavelength of 474 251 nm and a column temperature of 25 °C. The carotenoids were quantified using an external standard 252 of astaxanthin obtained from DSM (Heerlen, Netherlands).

253

# 254 **2.5 Skeletal development and spinal deformity**

255 Skeletal development and spinal malformation in smolt and harvest fish was assessed by x-ray 256 radiography. Twenty-five fish per tank/pen (n = 3) were euthanised using lethal anaesthesia (>200 257 mg L<sup>-1</sup> Tricaine, PHARMAQ UK), placed on flat trays and frozen at -20 °C prior to x-ray radiography. 258 Frozen fish were x-radiographed using a portable x-ray unit (Celtic SMR PX40 HF) with an 259 extremities plate measuring 24 x 30 cm. Each radiograph was exposed for 32 mAs and 40kV and the 260 image digitised (AGFA CR-35X). Radiographs were analysed using Adobe Photoshop CS 6 (version 261 13.0.1, Adobe system Incorporated, California, USA) with the spine divided into four regions, R1, 2, 262 3, and 4 as per Kacem et al. (1998) and deformity type categorised according to Witten et al. (2009). 263 Example pathologies were provided previously (Vera et al., 2019). Observations were made in the 264 anterior-caudal direction and the total number of vertebra was recorded for each fish.

265

#### 266 **2.6 Gene expression**

At the termination of the trial, a further 5 fish per pen were euthanised using lethal anaesthesia (>200 mg  $L^{-1}$  Tricaine, PHARMAQ UK) to provide samples for molecular analyses. Liver and muscle samples were aseptically dissected and placed in microcentrifuge tubes containing RNA-later for the

assessment of gene expression using microarray (liver transcriptome) and targeted gene expression through the application of real-time qPCR analysis of liver and muscle. The tissue samples were homogenised in 1 mL of TRIzol® (Invitrogen, UK) and total RNA extracted in accordance with the manufacturer's instructions. RNA pellets were rehydrated in MilliQ water, and total RNA concentration determined using an ND-1000 Nanodrop spectrophotometer (Labtech Int., East Sussex, UK), and RNA integrity assessed by electrophoresis.

- 276
- 277 2.6.1. Transcriptomic (microarray) analysis

278 Transcriptome analysis of liver (male only) was performed using an Atlantic salmon custom-made 279 oligoarray with 44 k features per array in a four-array-per-slide format (Agilent Technologies UK 280 Ltd., Wokingham, UK). A dual-label experimental design was used for the microarray hybridisations 281 with Cy3-labelled test samples competitively hybridised to a common Cy5-labelled pooled-reference 282 per array. A total of 15 arrays were employed, one array per individual fish. The common reference 283 was a pool of equal amounts of amplified RNA from all test samples. Indirect labelling was employed 284 in preparing the microarray targets. Amplified antisense RNA (aRNA) was produced from each RNA 285 sample using TargetAmpTM 1-Round Aminoallyl-aRNA Amplification Kit 101 (Epicentre, Madison, 286 Wisconsin, USA), as per manufacturer's methodology, followed by Cy3 or Cy5 fluor (PA23001 or 287 PA25001, GE HealthCare) incorporation through a dye-coupling reaction, as described by Betancor 288 et al. (2016). The hybridisations were performed using SureHyb hybridisation chambers (Agilent) in 289 a DNA Microarray Hybridisation Oven (Agilent). Sample order was semi-randomised, with one 290 replicate per experimental group being loaded into each slide. For each hybridisation, 825 ng of Cy3-291 labelled experimental biological replicate and Cy5-labelled reference pool were combined, following 292 the protocol described by Morais et al. (2012).

293

#### 294 2.6.2. Quantitative Real Time PCR

295 cDNA was reverse transcribed from 1 µg of total liver or muscle RNA using QuantiTect Reverse 296 Transcription kit (Qiagen Ltd., Manchester, UK). The resulting cDNA was diluted 20-fold with 297 milliQ water. Real-time PCR was performed using Luminaris color Higreen qPCR Master mix 298 (Thermo Fisher Scientific, MA, USA) and Mastercycler RealPlex 2 thermocycler (Eppendorf, UK) 299 which was programmed to perform the following protocol: 50 °C for 2 min, 95 °C for 1 min, followed 300 by 40 cycles at 95 °C for 15 s, annealing temperature (see Additional File 1) for 15 s and 72 °C for 301 30s. This was followed by a temperature ramp from 70 to 90 °C for melt-curve analysis to verify that 302 no primer-dimer artefacts were present and only one product was generated from each qPCR assay. 303 qPCR was performed in 96-well plates in duplicates per sample. The final volume of the PCR reaction 304 was 10 µL: 2.5 µL of cDNA, 5 µL of the qPCR Master Mix and 2.5 µL of forward and reverse primers. 305 The efficiency of the primers was verified and validated by doing standard curves for all genes 306 investigated. The new primers used in this study were designed using the software PRIMER3 307 (Untergasser et al., 2012). Target specificity was checked in silico using Blast (NCBI). Only primer 308 pairs with no unintended targets were selected (Additional File 1). The relative expression of target 309 genes in liver and muscle of salmon post-smolts was calculated by the  $\Delta\Delta$ Ct method (Pfaffl, 2001), 310 using  $\beta$ -actin, ef1a, polr2f and rpl1 as the reference genes, which were chosen as the most stable 311 according to RefFinder (Xie et al., 2012).

312 In liver, the genes investigated were involved in sterol metabolism (apolipoprotein B, acetyl-313 CoA carboxylase and cholesterol 7 alpha-hydroxylase), long-chain polyunsaturated fatty acid (LC-314 PUFA) metabolism (fatty acyl elongase 2, fatty acyl elongase 5 isoform b, fatty acyl elongase 6 and 315 delta-6 fatty acyl desaturase isoform a), immune system (interleukin 8, interleukin 1 beta, major 316 histocompatibility complex I and fas cell surface death receptor), 1-carbon metabolism 317 (*cystathionine-\beta-synthase*, *betaine-homocysteine* S-methyltransferase, methionine 318 adenosyltransferase1) and growth hormone receptor. In muscle, the expression levels of genes 319 involved in protein and energy metabolism (glucose transporter type 4, muscle-specific RING finger 320 protein 1a, muscle-specific RING finger protein 1b, autophagy-related protein 4 homolog B,

- autophagy related 12, microtubule-associated proteins 1A/1B light chain 3B precursor and GABA(A)
  receptor-associated protein), immune function (interleukin 1 beta) and growth (growth hormone
  receptor and insulin-like growth factor) were studied.
- 324

# 325 2.7 Statistical analysis

326 Growth and biochemical data were presented as means  $\pm$  SD and analysed using one-way analysis of 327 variance (ANOVA), general linear model, and pairwise comparison (Tukey) of means. Data were checked for homogeneity of the variances by the Bartlett test and, where necessary, the data were 328 329 transformed (arcsine or ln) for normalisation before further statistical analysis. Statistical tests were 330 performed using Minitab statistical software (Version 17<sup>©</sup>, University of Stirling, 2016). Data on 331 vitamins, minerals, free and hydrolysed amino acids were analysed using Statistica (ver13.4, Sibco 332 software inc.) by one way ANOVA and Tukey's post-hoc test when variances were homogenous, 333 otherwise with the Kruskal-Wallis ANOVA by Ranks. Differences were considered statistically 334 significant at p values < 0.05. Statistical analysis of microarray data was performed in GeneSpring 335 GX (Agilent Technologies, Wokingham, Berkshire, UK) using a Moderated t-test, at 0.05 336 significance. Data were submitted to the Kyoto Encyclopedia of Genes and Genomes (KEGG; 337 Kanehisa and Goto, 2000) for biological function analysis. The significance of differences in RT-338 qPCR data between dietary groups was determined using a one-way ANOVA followed by Tukey's 339 test, using SPSS v.19 software (IBM, Armonk, NY), with significance level fixed at p < 0.05.

340

#### **341 3. Results**

# 342 **3.1 Mortality, growth and maturation**

There were no significant differences in cumulative mortality between dietary treatments in freshwater or seawater (Table 5). Diet had a significant effect on weight, growth rate (TGC<sub>wt</sub>) and bFCR in both freshwater and saltwater (Fig. 1, Table 5). Fish fed diet L2 achieved the highest final smolt weight, with fish fed diet L1 significantly lower, and diet L3 intermediary to both. This pattern was mirrored by similar significant dietary effects on TGC<sub>wt</sub> and bFCR. Final smolt K factor
decreased with increasing NP inclusion level. Diet did not significantly affect VSI, while HSI was
significantly lower in salmon fed diets L2 and L3 than fish fed diet L1 at smolt.

350 In seawater, fish fed diets L2 and L3 achieved a significantly higher final weight than those 351 fed diet L1, but did not differ significantly between each other. Moreover, a trend was clearly evident 352 in TGC<sub>wt</sub>, which increased with increasing NP inclusion level (Table 5). In particular, salmon fed diet 353 L3 were transferred to sea at a significantly lower smolt weight than those fed diet L2, but achieved 354 a comparable body weight to fish fed diet L2 within 4 months of seawater transfer (Fig. 1). Final K 355 factor also showed a significant increase with increasing dietary NP inclusion level, and bFCR was 356 significantly lower in fish fed diets L2 and L3 than diet L1. Both VSI and HSI were not significantly 357 different at harvest between diets, and no statistical differences in maturation rates (predominantly 358 males), were observed between fish fed the different diets.

359

# 360 **3.2 Radiological deformity**

361 Externally visible malformation was <1 % at the end of both freshwater and seawater phases, but 362 radiologically detected spinal deformity was significantly affected by diet (Fig. 2). There was a 363 progressive reduction in detectable malformation in fish with increasing NP inclusion level. At smolt, 364 fish fed diet L3 had significantly lower detectable deformity than fish fed diet L1, and diet L2 was 365 intermediary to both. The predominant region affected with spinal malformation was in the caudal 366 trunk region (R2), with v24-28 the most commonly affected vertebral bodies. At the end of the 367 seawater phase, there was an increase, albeit non-significant, in detectable deformity in fish fed diets 368 L1 and L2 to that observed at smolt, and the pattern was maintained whereby salmon fed diet L3 had 369 significantly lower deformity than those fed diet L1, and diet L2 was intermediary to both. The 370 predominant region affected with spinal malformation was in the tail region (R3), posterior to the 371 dorsal fin, with v38 - 44 the most commonly affected vertebral bodies. Most deformities presented 372 themselves as compressive type pathologies (~53 % of total pathology) followed by reduction in

intervertebral spacing (~30 %) and, finally, more severe, fusion-type lesions (~15 %), and was
generally similar across all diets.

375

#### 376 **3.3 Whole body composition and nutrient retention**

377 Post-smolts had similar whole body composition independent of dietary NP inclusion level, with the 378 exception of whole body ash that was significantly higher in salmon fed diet L3 than those fed diets 379 L1 or L2. Whole body Zn and Se concentration increased significantly with increasing NP inclusion 380 (Table 6). Retention of Cu decreased with increased NP inclusion, while Se retention was 381 significantly higher in L3 than both L1 and L2. Remaining nutrient retentions did not differ between 382 fish fed the different diets. NOC composition was generally comparable between diets, however there 383 was a significantly higher total lipid in fish fed diet L3 than those fed diets L1 or L2. As a percentage 384 of total fatty acids, n-6 long-chain polyunsaturated fatty acids (LC-PUFA) and docosahexaenoic acid 385 (DHA; 22:6n-3) decreased with increasing NP inclusion level

386

# 387 3.4 Total amino acid concentration in whole body and free amino acids and N-metabolites in 388 white muscle tissue

Whole body histidine and lysine retention decreased with increasing NP inclusion level, while all other amino acid retentions were similar between fish fed the different diets (Table 7). Muscle content of free OH-Pro, serine and glycine significantly decreased with increasing NP inclusion, while free histidine, increased significantly with NP inclusion level (Table 8).

393

# **394 3.5 Tissue water soluble vitamin status and retention**

Vitamin C showed higher concentrations in whole body of fish fed L2 and L3 than in those fed L1.
Vitamin C concentration in liver was not significantly different between fish fed the three diets, but
the trend was that vitamin C increased from L1 to L2 and then decreased again in fish fed L3. Whole
body pantothenic acid and niacin increased significantly with increasing NP inclusion, while

399 concentrations of the other B-vitamins in whole body were comparably independent of dietary NP 400 inclusion level (Table 9). Riboflavin retention and the retention of folate decreased significantly with 401 increasing NP inclusion, while thiamine, niacin and biotin showed no significant effect of NP 402 inclusion. Tissue specific concentrations (liver, gill and muscle) of the measured B-vitamins were 403 comparable and independent of dietary NP inclusion level, although there was a trend for increasing 404 gill pantothenic acid and muscle vitamin B6 concentration with increasing NP inclusion.

405

# 406 **3.6 Tissue lipid soluble vitamin status and retention**

407 With the exception of vitamin  $K_1$  and  $\gamma$ -TOH (tocopherol), all other lipid soluble vitamins in whole 408 body and tissue (liver and muscle) showed a significant increase in concentration with increasing NP 409 inclusion level (Table 10). Whole body  $\alpha$ -TOH retention increased with NP inclusion level.

410

# 411 **3.7 Gene expression**

#### 412 3.7.1 Liver transcriptome

413 Transcriptome analysis was performed on liver tissue in individual male fish (n = 5). Statistical 414 analysis of the microarray data returned a list of 306 and 360 annotated differentially expressed genes 415 (DEG) in liver of salmon fed the L2 and L3 diets, respectively, when compared to fish fed diet L1 416 (moderated t-test, p < 0.05 and fold-change > 1.3). In addition, a total of 396 genes were differentially 417 expressed (fold-change > 1.3) in the liver of salmon fed diet L3 when compared to fish fed diet L2. 418 Functional analysis for all contrasts (Kyoto Encyclopedia of Genes and Genomes, [KEGG] 419 Orthology) showed a similar distribution by categories of DEG, with the major categories being 420 metabolism, signal transduction and immune system. Within metabolism, the most represented 421 category was lipid metabolism in all cases (Fig. 3). Pathway analysis showed that the top significant 422 differentially expressed pathways in the L2 vs. L1 comparison were: PI3K-Akt signalling pathway, 423 protein processing in endoplasmic reticulum, steroid biosynthesis, sphingolipid signalling pathway, 424 phagosome and focal adhesion (Additional File 2). Moreover, the most represented metabolic 425 pathways suggested a downregulation of lipid metabolism (steroid biosynthesis, sphingolipid 426 metabolism, glycerophospholipid metabolism, glycerolipid metabolism and arachidonic acid 427 metabolism) in fish fed diet L2 compared to the L1 diet (Fig. 4A, Additional File 3). Regarding the 428 L3/L1 contrast, the top significant differentially expressed pathways were PI3K-Akt signalling 429 pathway, regulation of actin cytoskeleton, MAPK signalling pathway, Rap1 signalling pathway, NF-430 kappa B signalling pathway, focal adhesion and chemokine signalling pathway (Additional File 4). 431 In this case, most genes involved in lipid and amino acid metabolism were downregulated whereas 432 oxidative phosphorylation and glycolysis were upregulated (Fig. 4B, Additional File 3).

In order to identify common functional categories affected by micronutrient supplementation results from each pairwise contrast were intersected, obtaining a list of 138 common features corresponding to a total of 58 annotated genes. The most affected biological categories for L3/L1 were metabolism (27 %), signal transduction (15 %), immune system (9 %) and endocrine system (8 %). Within metabolism the most represented category was lipid metabolism at 11 % (Additional File 5).

439

# 440 3.7.2 Gene expression by qPCR

441 In liver, the expression of genes involved in sterol metabolism (apoB, cyp7a1) did not differ 442 significantly between diets, although there was a trend for increased apoB expression with NP 443 inclusion level (Table 11). Regarding genes involved in fatty acid and LC-PUFA metabolism, 444 fads2d6a showed a significant decrease in fish fed diet L2 relative to fish fed diet L1, and diet L3 445 intermediary to both. Expression of *elovl2* was significantly higher in fish fed diet L2 than those fed 446 diet L3, with diet L1 intermediary to both. Other genes (acc, elov15, elov16, fas) showed no significant 447 effect of diet, although there was a trend for increased *acc* expression with increasing NP inclusion. 448 Genes involved in 1-carbon metabolism (cbs, bhmt, mat1) and immune functions (il8, il1b) did not 449 differ between fish fed the different diets. Finally, *ghr* expression was significantly higher in salmon 450 fed diet L1 than those diet L2, with diet L3 intermediary to both.

451 In muscle, the expression of some genes involved in autophagy and protein turnover (*atg12*, 452 gabarap, murfla, mlp3b) showed significantly increased expression in salmon fed diet L3 relative to 453 those fed diet L1, and diet L2 intermediary to both (Table 11). In addition, *atg4b*, and *murf1b* showed 454 the same trend although differences between groups were not statistically significant. Differences 455 between dietary groups for genes involved in growth and glucose transport (ghr, igf, glut4) were not 456 significant. However, the pattern of *ghr* expression in muscle mirrored that of *ghr* in the liver, with 457 fish fed diet L2 having lowest expression and those fed diet L1 highest, while *igf* expression showed 458 a trend of increased expression with increasing NP inclusion. Finally, genes associated with immune 459 function (*il1bm*) were not statistically different in muscle of post-smolt salmon.

460

#### 461 **4. Discussion**

# 462 **4.1 Growth**

463 In the current long-term study utilising S0+ Atlantic salmon parr, growth in freshwater and the pattern 464 of final smolt body weight between diets mirrored that previously reported in S1+ Atlantic salmon 465 parr fed the same diet formulation (Taylor et al., 2019). In both studies, fish fed diet L2 (2xNP) 466 achieved a significantly higher final smolt weight, than fish fed diets L1 and L3, which was reflected 467 in an improved growth rate (TGC<sub>bw</sub>) and more efficient FCR. In both studies, irrespective of smolt 468 regime, diet L3 (4xNP) initially showed an increased growth rate relative to diet L1 (1xNP), but 469 subsequently decreased, resulting in a final smolt weight intermediary to diets L1 and L2. This growth 470 reduction occurred around 14 weeks post-feeding in the S1 salmon (Taylor et al., 2019) and within 4 471 weeks of feeding under the S0+ regime in the current study. These results are in contrast to Hemre et 472 al. (2016) and Prabhu et al. (2019), where parr were fed similar dietary formulations for 12 weeks but 473 a decrease in growth rate beyond 2xNP was not observed. However, parr were not taken through parr-474 smolt transformation (PST) in that short-term study. Of note, in both S1+ (Taylor et al., 2019) and the current S0+ part study, the occurrence of growth reduction commenced at the start of the rising 475 476 day length in spring (ambient in S1+; and following switch from LD 14:10 to LL in S0+). Given that

there are significant morphological, physiological and metabolic transformations during PST (Hoar, 1988), then there may be differing dietary requirements and nutrient re-profiling during this transition. As such, the current study suggested certain components in NP could be in "excess" or detrimental to growth when supplemented at >2xNP levels, particularly in Atlantic salmon undergoing PST. However, both the current study and that of Taylor et al. (2019) have not been able to conclusively ascertain which components and/or interactions within the NP were detrimental, and further studies are clearly warranted to elucidate this apparent phenomenon.

484 In seawater, growth rate (TGC<sub>bw</sub>) improved linearly with increasing NP, and bFCR was more 485 efficient in fish fed diets L2 and L3 than L1, such that fish fed diet L3 while initially stocked at a 486 significantly smaller body weight at smolt, attained a body weight comparable to that of fish fed diet 487 L2 at harvest. By contrast, Hemre et al., (2016) did not find a strong effect of graded NP on growth 488 rate in post-smolts, but this may in part be related to differences between the former and current study: 489 shorter duration (5 months vs. 12 months), cooler water temperatures experienced (4.1-10 °C vs. 6-490 16 °C) and subsequently lower TGC<sub>bw</sub> (2.37-2.55 vs. 2.9-3.1). Nonetheless, with the progressive 491 reduction of FM and FO down to 5 % and 3 % during the current trial, results do confirm and support 492 the earlier shorter-term studies (Hamre et al., 2016; Hemre et al., 2016; Taylor et al., 2019; Prabhu et 493 al., 2019) that specific components of the NP are required to be supplemented at between 2x and 4x 494 current recommendation when utilising high plant-based diets for the duration of the life cycle. The 495 specific components of the NP that are associated with improvements in growth and performance will 496 be discussed in subsequent nutrient status sections.

497

# 498 **4.2 Skeletal Health**

In contrast to growth, we observed a clear linear decrease in radiological deformity with increasing NP inclusion in freshwater which concurs with results from our previous short-term feeding study (Vera et al 2019). Further, in the current study, there was also a progression of spinal pathology in post-smolts when reassessed at harvest compared to initial smolt in fish fed diets L1 and L2, while 503 diet L3 showed no further increase in pathology. Concomitantly, spinal deformity was also inversely 504 correlated with final whole body ash concentration, a widely accepted indicator of body/bone 505 mineralisation (Baeverfjord et al., 2019), indicating increasing NP level improved post-smolt mineral 506 status. Previously, upregulation of bone gene expression associated with extracellular matrix (ECM) 507 mineralisation (ALP, Mgp, Ostcn), and corresponding decrease in skeletal pathology was observed 508 following increased NP supplementation in parr (Vera et al., 2019). Effects were hypothesised to be 509 mediated through altered P-Ca homeostasis pathways, as reflected by increased whole-body Ca:P 510 ratios in smolts. Candidate components of the NP were suggested as vitamins D<sub>3</sub> and K as cofactors 511 of calcium sequestering. However, in the current study, improved mineralisation was not explained 512 by differences in whole body macromineral concentration or retention in post-smolts which were 513 similar across all diets and in the normal range for salmon (Shearer et al., 1994). Similarly, Fjelldal 514 et al. (2009) reported a reduction in vertebral deformity at 4.1 kg in S0+ post-smolts fed a high mineral 515 diet for the first 8 weeks post sea entry, and while analysis of plasma Ca, P and D-vitamin metabolites 516 reflected changes in P homeostasis, these factors could not explain the preventive effect of a high 517 mineral diet on development of bone deformities. To this end, given that analysed dietary vitamin D<sub>3</sub> 518 and K in the current formulation were within established requirement ranges of 0.15-0.19 mg kg<sup>-1</sup> (NRC, 2011) and >0.1 mg kg<sup>-1</sup> (Krossøy et al., 2009) respectively, it is unlikely these components of 519 520 the NP are directly attributable to the graded decrease in spinal pathology observed in post-smolts, 521 and other components of the NP are worth consideration.

Whole body Zn and Se increased across diets with NP inclusion rate, with both being identified as the principal limiting micro-minerals in plant-based diets (Prabhu et al., 2018; Prabhu et al., 2019). Selenium is involved in antioxidant mechanisms and redox reactions in liver and blood cells, yet the role of Se in bone metabolism remains unexplored in salmonids to date (Baeverfjord et al., 2019). Recent studies have shown that Se, in the form of selenoproteins, plays a vital role in bone metabolism in humans (Pietschmann et al., 2014), with plasma selenoprotein P concentrations found to positively correlate with bone mineral density in elderly women (Zhang et al., 2014). As such, although whole body Se levels across all diets were within the normal reported range for Atlanticsalmon (Prabhu et al., 2016), the role of Se in teleost bone development should be investigated.

531 It is well established that Zn is the most abundant micro-mineral in the vertebrae of many 532 teleost fish species and has functional importance in the activity of ALP, and associated processes 533 related to mineralisation of bone (Prabhu et al., 2016). Thus, improved Zn status and downstream 534 processes may be directly attributable to the observed reduction in spinal pathology and progression 535 as post-smolts, particularly in fish fed diet L3 (4xNP). While studies on spinal development have 536 often focused on dietary macro- and micro-minerals, the role of specific vitamins within the NP 537 should not be overlooked as having a beneficial effect on skeletal health. Whole body vitamin A 538 levels suggested that diet L1 covered minimum requirement (>0.75mg kg<sup>-1</sup>, Moren et al., 2004), and 539 diet L3 had significantly lower skeletal deformity. Diet L1-L3 in this study contained 3.7-12.2mg 540 kg<sup>-1</sup> VA, well below the upper limits shown to induce skeletal pathology (>37 mg kg<sup>-1</sup>) (Ørnsrud 541 et al., 2002; Ørnsrud et al., 2013). Therefore, it is unlikely that vitamin A deficiency or 542 hypervitaminosis is attributable to the differences in spinal deformity rates observed. The specific 543 role of B-vitamins on bone development in humans has been documented to a degree (Dai and Koh, 544 2015) but, as yet, has not been investigated in fish (Lall & McCrea, 2007). Evidence from humans as 545 reviewed by Dai and Koh (2015) has shown a variety of effects of vitamin B deficiencies including: 546 reduced dietary intake of B6 is associated with lower bone mineral density; synthesis of methionine 547 depends on both folate and B12 for remethylation, and deficiency of either B vitamin results in 548 megaloblastic changes in bone marrow; B vitamin deficiency affects the anatomical/biochemical 549 properties of bone if it is profound enough to cause hyperhomocysteinemia that is sufficient to induce 550 an accumulation of homocysteine in the bone tissue. In light of the growing research in B vitamin 551 involvement in bone metabolism in humans, greater consideration of B vitamin requirements in fish 552 would also warrant consideration in relation to skeletal health.

553

# 554 **4.3 Protein and amino acid status and retention**

555 The present study increased dietary taurine and histidine keeping the methionine constant in high 556 plant protein diets for Atlantic salmon growing from parr to approximately 2.5 kg BW. NRC requirement for methionine in Atlantic salmon is reported to be 7 g kg<sup>-1</sup> (NRC 2011). However, it 557 was previously reported that dietary methionine of 7.9 vs 11.4 g kg<sup>-1</sup> methionine improved growth 558 559 and hepatosomatic index in salmon fed the latter diet (Espe et al., 2014). In another study, Atlantic 560 salmon fed high plant protein diets containing either 8 or 11 g methionine per kg of diet, the weight gain in the latter diet did not differ from the control group fed a high fishmeal diet (760 g kg<sup>-1</sup> diet). 561 562 Thus, in the current trial it was decided to maintain the dietary methionine constant at around 9 g kg<sup>-</sup> 563 <sup>1</sup> diet, while histidine and taurine were increased in the nutrient packages.

564 The retention of amino acids is known to be high when an amino acid is slightly deficient and 565 then decrease as the requirement for amino acid deposition is met or increased above requirement for 566 protein deposition (Espe et al., 2017). In the current study this is also true for histidine, where 567 retention decreased as dietary histidine increased. In addition to histidine, lysine retention was also 568 reduced in salmon fed the L3 diet as compared to fish fed the L1 and L2 diets. Lysine is mainly used 569 for protein deposition (Espe et al., 2007) and the reduced retention of lysine in fish fed the highest 570 nutrient package thus might indicate a lower protein gain in muscle of these fish. However, as protein 571 retention did not differ in fish fed any of the diets, reduced lysine retention does not seem to be 572 associated with a reduced muscle protein deposition in the current trial. Thus, to address the reduced 573 retention of lysine, interaction with other nutrients in the NP needs to be further explored. It is well 574 known that both amino acid supply and the balance between dietary amino acids affect growth 575 hormone, IGF and GH (Hevrøy et al., 2007; Bower et al., 2008; Valente et al., 2012). In the current 576 trial these were not affected, which supports the fact that protein retention did not differ between fish 577 fed any of the diets in the current trial.

Any imbalanced supply of amino acids may increase the ubiquitination and thereby degradation of proteins (Bower et al., 2008; Valente et al., 2012). The gene expression level of *murf*, *gabarab* and *atg12* were higher in the higher nutrient package in the current trial, but this is more 581 likely due to a higher degradation of soluble protein than the degradation of muscle protein. However,582 this also needs to be addressed in new trials using fewer variables.

583 As expected, free histidine in muscle increased as dietary histidine increased simply reflecting 584 the higher dietary histidine content in line with previous results (Remø et al., 2014). Taurine in muscle 585 on the other hand did not increase following increased dietary taurine. This is most likely is due to 586 increased excretion of excess taurine or that the taurine fed is directed to other tissues such as the 587 liver (Espe et al., 2012a, 2012b). Both dietary histidine and taurine are more associated with oxidation and protection against ROS than with growth and metabolism (Remø et al., 2014) as well as survival 588 589 of the cells (Espe and Holen, 2013), but these aspects were not addressed in the current trial. In 590 addition, dietary taurine has been reported to reduce the visceral fat in salmon (Espe et al., 2012a, 591 2012b), but as neither HSI nor VSI were affected by increased inclusion of NP, the L1 diet appears 592 to contain sufficient taurine to not significantly affect adiposity in salmon in the current trial.

Finally, free OH-proline decreased with increased nutrient package which might be due to an interaction with some of the other micronutrients fed, e.g. vitamin C. It is, however, unlikely that the lower OH-pro in fish muscle of fish fed the L3 diet is associated with any increased muscle degradation as deposition and growth actually was greatest in this group, although protein retention did not differ between the groups.

598

# 599 **4.4 Water-soluble vitamins**

Since growth was improved when increasing the nutrient package, without increasing methionine, the other components must have affected growth positively without the present level of methionine being critical, e.g. some of the B-vitamins will be critical for salmon to obtain maximum growth (Hemre et al., 2016), as well as some of the minerals (Prabhu et al., 2019a, b). In an experiment with salmon parr, it was estimated that the 2xNP would cover requirement for several micronutrients, especially when given with high plant raw material diets (Hemre et al., 2016, Hamre et al., 2016, Prabhu et al., 2019a). The present study, therefore, confirmed earlier conclusions that plant-based diets need new requirement estimates for several micronutrients. The suggested body-concentrations,
health outcomes and growth response used as requirement markers were not sufficient in the former
study (Hemre et al., 2016), and the present study confirmed this.

Pantothenic acid in whole body was higher in fish fed diets L2 and L3 compared to diet L1, while niacin increased gradually from L1 to L3, significantly at each step. Pantothenic acid in gill tissue also increased but differences were not significant. There was also a tendency for higher B6 concentration in whole body in fish fed diets L2 and L3 compared to L1. This is in agreement with earlier findings for salmon post-smolt (Hemre et al., 2016). These results suggest that these three Bvitamin optimal levels should be raised when compared to NRC (2011), to the 2xNP level for pantothenic acid and B6 and to the 4xNP level for niacin.

617 Vitamin B6 interacts highly with protein metabolism (Hansen et al., 2015). Pyridoxine 618 functions as phosphorylated coenzymes pyridoxal phosphate (PLP) in many reactions, such as 619 transaminases in amino acid metabolism. Pyridoxine is a cofactor for the enzyme aromatic amino 620 acid decarboxylase, which is required for the synthesis of neurotransmitters (Rorsman et al., 1995). 621 Therefore, symptoms and consequences of vitamin B6 deficiency are many, diverse and severe, and 622 include nervous disorders and abnormal behavior, none of which was registered in the present study. 623 Tissues with mitochondria-rich cells and cells that undergo rapid cell divisions like gill tissue are 624 especially sensitive to pantothenic acid deficiency. The 1xNP levels seemed to be sufficient for the 625 other B vitamins (thiamine, riboflavin, folic acid and biotin), as found by Hemre et al. (2016). There 626 was, however, a tendency for a decrease in retention of B-vitamins, significant only for riboflavin 627 and folate. This may point to either an interaction and/or control factor at the gut-barrier level, or 628 excretion of excess vitamin, since whole body levels were maintained or increased.

Vitamin C in whole body increased from diet L1 to L2 and was then unchanged in fish fed diet L3. This is in accordance with previous results (Hamre et al., 2016). In the liver, changes in vitamin C concentrations were not significant (p = 0.06), but there was a tendency for an increase in fish fed diet L2 compared to L1, and then a decrease in fish fed L3. The variation was very high in both the L2 and L3 groups. It is well known that vitamin C may act as a pro-oxidant at high
concentrations (Hamre et al., 1997), and this may indicate that diet L3, and perhaps L2, contained too
much vitamin C, and an optimal vitamin C level at the 2xNP level or slightly less is needed.

636

# 637 **4.5 Lipid soluble vitamins**

638 Lipid soluble vitamins have a tendency to accumulate in the body in response to increased 639 supplementation. Therefore, it is not possible to use body concentrations as an indication of 640 requirement. This is true for α-tocopherol (TOH) which normally shows a linear relationship between 641 supplementation and whole body concentration (Hamre et al., 1997; Hamre et al., 2016) as confirmed 642 in the present study. Hamre et al. (2016) recommended supplementation with at least 150 mg kg<sup>-1</sup>  $\alpha$ -TOH to compensate for variations in composition of feed ingredients and variation in oxidative stress, 643 644 in response to handling, seasons and disease. TOH was not supplemented, but came from the feed 645 ingredients, and the feed and whole body concentrations did not vary among the dietary treatments.

For vitamin A, the situation is more complicated due to the presence of many different forms. 646 647 Most of the vitamin A is present in the storage form retinol-esters (Moren et al., 2004), and the method 648 used here determined esters and free forms combined. However, both free retinol and retinol esters 649 increased exponentially with increasing concentration of vitamin A in the diet, and there was a large increase in body stores with an increase of dietary retinol equivalents from 0.75 to 2.5 mg kg<sup>-1</sup> diet. 650 Nevertheless, a requirement was found in Atlantic halibut of 2.5 mg kg<sup>-1</sup> diet based on cell 651 652 proliferation in the intestine as measured by DNA content, PCNA and maturity of the brush border 653 membrane by enzyme activities (Moren et al., 2004). With reference to Moren et al. (2004) and the whole body levels found here, diet L1 had enough vitamin A (3.7mg kg<sup>-1</sup>) to cover the requirement 654  $(\geq 0.75 \text{ mg kg}^{-1}\text{NRC}, 2011).$ 655

The diets were supplemented with the synthetic pro-vitamin K, menadione (vitamin K3). Menadione is very unstable during feed processing (Krossøy et al., 2009), and the analysed dietary levels of K3 were only 1/10 of the supplemented levels. Menadione is metabolised to menakinones (MK4-13, vitamin K2) in the body (Krossøy et al., 2011) and therefore, MK4 increased in response to increase in dietary vitamin K3, while whole body vitamin K1 was similar in fish fed the different treatments. Krossøy et al. (2009) fed Atlantic salmon eight diets supplemented with 0 to 50 mg kg<sup>-1</sup> vitamin K3 and found no effects on fish performance, or blood coagulation time and vertebrae stiffness. They concluded that the feed ingredients probably contained enough vitamin K (0.1 mg kg<sup>-1</sup>) to cover the requirement, which is consistent with the findings in the present study. Estimated requirements in other species range from 0.2 to 2 mg kg<sup>-1</sup> (NRC 2011).

Vitamin D was supplemented at 0.05, 0.10 and 0.20 mg kg<sup>-1</sup>, but the analysed levels in muscle were 0.15-0.19 mg kg<sup>-1</sup>, reflecting that the ingredients contained significant amounts of vitamin D<sub>3</sub>. Marine feed ingredients usually contain ample amounts of vitamin D and this may be the reason that vitamin D requirements in Atlantic salmon have been difficult to define. Furthermore, high doses of vitamin D up to 57 mg kg<sup>-1</sup> seem to be well tolerated by Atlantic salmon (Horvli et al., 1998; Graff et al., 2002). In other fish species estimated requirements vary from 0.006 to 0.060 mg kg<sup>-1</sup> (NRC 2011), well below the supplementation levels in the present study.

673

# 674 **4.6 Minerals**

675 Optimal supply of dietary micro-minerals is essential to maintain body mineral homeostasis 676 (Watanabe et al., 1997). Deficient or sub-optimal supply of dietary micro-minerals will deplete body 677 mineral status, especially over the long term (Maage & Julshman, 1993). The NPs had graded levels 678 of micro-minerals of which Zn and Se increased with increasing NP inclusions from diets L1 to L3. 679 In plant-based salmonid feeds, Zn and Se have been identified as the most limiting micro-minerals 680 (Prabhu et al., 2018, 2019a). In Atlantic salmon parr and post-smolt, dietary Zn levels of 101-132 mg kg<sup>-1</sup> and 140-177 mg kg<sup>-1</sup> respectively supplied by NP inclusion of 100-150 and 150-200 were able 681 682 to meet the Zn requirement over the short-term (Prabhu et al., 2019a). Herein, on a long-term basis with an almost 30-fold increase in weight during the trial period, the L1 diet with 94 mg Zn kg<sup>-1</sup> 683 684 decreased the Zn status to half and one-third in L2 and L3 fed-fish, respectively. Similar reductions

in whole body Zn ranging from  $\frac{1}{3}$  to  $\frac{1}{2}$  were observed in Atlantic salmon part fed sub-optimal Zn 685 686 levels (Maage & Julshman, 1993). The L2 diet with 156 mg Zn kg<sup>-1</sup> was able to sustain the body Zn status on parr to the initial Zn status (18 mg kg<sup>-1</sup> wet weight). However, the initial Zn status of the 687 688 Atlantic salmon in this study was lower than values reported in the literature for similar size fish 689 (Maage & Julshman, 1993; Shearer et al., 1994). The Zn status of Atlantic salmon fed the L2 diet (18 mg kg<sup>-1</sup> wet weight, averaging 2.3 kg) was considerably lower than the Zn status of 27-29 mg kg<sup>-1</sup> of 690 691 500 g post-smolt fed similar Zn levels in a previous trial (Prabhu et al. 2019a). Se levels in all three 692 dietary groups were in the normal range observed in salmonids or Atlantic salmon specifically 693 (Prabhu et al., 2016), mostly because the high background Se levels in basal diet already met the 694 requirement. Although the NP composition did not change between the present and previous studies 695 (Hamre et al., 2016; Prabhu et al., 2019a), the total dietary Se levels were considerably different for 696 corresponding NP inclusions, thereby Se recommendations differ between studies. Variation in Se 697 content of feed ingredients have to be considered in feed formulations and regulative legislation. The 698 supplementation of manganese of 12 mg/kg diet in diet L1 corresponding to a total dietary Mn of 42 699 mg/kg diet was sufficient to maintain normal body status. Recently, Prabhu et al. (2019b) also showed 700 that Mn supplementation of 14 mg/kg as MnSO<sub>4</sub> satisfied the minimal dietary requirement of Atlantic 701 salmon post-smolt fed plant-based diets. The macro-mineral composition was within normal range 702 and unaltered in Atlantic salmon fed the different diets implying the diets met the macro-mineral 703 needs of Atlantic salmon over the entire study period. Overall, Atlantic salmon post-smolt in seawater 704 were able to maintain their body status in the long run with minimal dietary supply of most micro-705 minerals from the L1 diet, except for Zn which required L2 levels.

706

# 707 **4.7 Gene Expression**

In general, the number of significantly differentially regulated functional pathways were greater for the L3 vs. L1 dietary comparison, than for the L2 vs. L1 comparison. In fact, not only the number of up- or down-regulated pathways was higher in L3/L1, but also the number of DEGs involved in each 711 pathway was greater, suggesting a correlation between increased dietary micronutrient 712 supplementation in low marine diets and changes in liver transcriptome. Regarding the effects on 713 specific pathways, in both diet comparisons (L3/L1 and L2/L1), the terpenoid backbone and steroid 714 biosynthesis pathways were down-regulated. A micronutrient dependent epigenetic gene regulation 715 of the upstream regulator (acetyl-CoA carboxylase alpha, acaca) that provides malonyl-CoA 716 substrate for the biosynthesis of fatty acids has been demonstrated (Saito et al, *publication pending*). 717 The terpenoid backbone pathway underpins cholesterol (sterol), heme and vitamin (retinoids, retinol, 718 retinoic acid, menadione) synthesis while both biosynthetic pathways are involved in steroid (e.g. 719 testosterone) hormone production. The steroid and sterol biosynthetic pathways were also the most 720 significantly affected in zebrafish offspring after feeding the parental generation a diet deficient in 721 micronutrients (vitamin B12, vitamin B6, folic acid, methionine and choline) (Skjaerven et al., 2018). 722 Further, the offspring from deficient parents had accumulated higher levels of lipid inclusion in the 723 hepatocytes and showed a downregulation in the steroid biosynthetic process and widespread 724 epigenetic changes of gene regulation in the liver (Skjaerven et al., 2018). This suggests that 725 micronutrient supplementation may not only be affecting nutrient retention directly, but also via 726 epigenetic mechanisms altering gene regulation and downstream biochemical process.

727 These effects on gene expression may be in response to the increased supplementation of the 728 L2 and L3 diets with cholesterol, menadione (vitamin K) and retinol (vitamin A) as part of the 729 micronutrient premix and therefore reflect an increased requirement of these compounds in fish fed 730 diet L1 (Kortner et al., 2014). The lower level of dietary pantothenic acid could also have affected 731 the up-regulation of several metabolic pathways in fish fed diet L1. Pantothenic acid is required for 732 synthesis of coenzyme A, which participates in a range of acyl transfer reactions in energy production, 733 fatty acid oxidation, cholesterol and steroid synthesis, heme synthesis, amino acid catabolism, 734 acetylcholine synthesis and many other acetylation and acylation reactions (Olsvik et al., 2013).

Increased expression of genes related to glyoxylate/dicarboxylate metabolism was observed
in salmon fed diet L1 in comparison to fish fed L3, suggesting lower levels of glucose in liver of L1

737 salmon and therefore the need to synthesise it from fatty acids. Meanwhile, an activation of 738 intermediary metabolism in fish fed diet L3 may indicate higher levels of glucose available for energy 739 production, and an enhancement of cellular energy levels as suggested by the increased number of 740 up-regulated genes in glycolysis/gluconeogenesis, and oxidative phosphorylation pathways in fish 741 fed diet L3. The differences in hepatic metabolic activities, energy generation and transport and 742 growth performance between salmon fed diets L3 and L1 could be linked to the higher levels in L3 743 fish of B vitamins (riboflavin, niacin), which are involved in a range of cellular processes, most 744 importantly energy generation and transport that enables fish fed diet L3 to sustain vital metabolic 745 processes without compromising the amount of energy available for growth (Hansen et al., 2015).

746 The q-PCR results of genes involved in LC-PUFA biosynthesis showed down-regulation of 747 biosynthesis with increasing micronutrient supplementation. A down-regulation of fads2d6a was 748 found, indicating greater LC-PUFA biosynthesis capacity in the liver of L1 salmon. However, these 749 differences were not fully reflected in hepatic n-3 LC-PUFA profiles in the present study, which 750 showed no major differences between the dietary groups. In muscle, *mlp3b*, *atg12* and *gabarap* genes 751 were found to be upregulated in L3-fed salmon. These genes are involved in autophagosome mediated 752 autophagy, playing an important role in autophagosome formation and sequestration of cytosolic 753 cargo into double membrane vesicles, leading to subsequent degradation after fusion with lysosomes 754 (Mannackand Lane, 2014).

755

# 756 **5.** Conclusions

The present study as part EU ARRAINA project, confirmed earlier studies (Hamre et al., 2016; Hemre et al., 2016; Prahbu et al., 2019; Taylor et al., 2019; Vera et al., 2019) that plant-based diets for Atlantic salmon need new requirement estimates for several micronutrients. In particular, these optimal levels may differ between freshwater and seawater phases of the production cycle, and that requirements for growth and skeletal health may also differ. Based on the present results and conclusions from earlier studies (Hamre et al., 2016; Hemre et al., 2016; Prahbu et al., 2019a; Taylor et al., 2019; Vera et al., 2019), NRC (2011) should be revised for diets in which plants form the major
part of the ingredient mix. For these plant-based diets most B-vitamin optimal levels were met at the
NRC (2011) recommendations, but beneficial effects were found with moderately increased levels
(L2) of niacin, riboflavin and cobalamin, vitamin C, and the minerals Zn and Se. However, as
indicated in all previous studies, too high levels of the micro-nutrient package (L3) may reduce these
beneficial effects.

769

# 770 5. Acknowledgements

This study was funded by the European Commission FP7 Integrated Project No. 288925, Advanced

772 Research Initiatives for Nutrition & Aquaculture (ARRAINA). A special thanks goes to all technical

staff at the Niall Bromage Freshwater Research Facility, Stirling and the Ardnish Feed Trial Unit,

T74 Lochailort, MOWI Scotland for care and maintenance of the animals.

775

# 776 **6. References**

- Baeverfjord, G., Prabhu, A.J.P., Fjelldal, P.G., Albrektsen, S., Hatlen, B., Denstadli, Y., Ytteborg, E.,
  Takle, H., Lock, E.-J., Berntssen, M.H.G, Lundebye, A.K., Åsgård, T., Waagbø, R. 2019.
  Mineral nutrition and bone health in salmonids. Rev. Aquacult. 11, 740-765.
- Betancor M.B., Olsen, R.E., Solstorm, D., Skulstad, O.F., Tocher, D.R. 2016. Assessment of a landlocked Atlantic salmon (*Salmo salar* L.) population as a potential genetic resource with a focus
  on long-chain polyunsaturated fatty acid biosynthesis. Biochim Biophys Acta 1861, 227-238.
- Bower, N.I., Li, X., Taylor, R., Johnston I.A. 2008. Switching to fast growth: the insulin-like growth
  factor (IGF) system in skeletal muscle of Atlantic salmon. J. Exp Biol. 211, 3859-3870
- CEN, 1999. Foodstuffs Determination of vitamin E by high performance liquid chromatography Measurement of alpha-, beta-, gamma- and delta-tocopherols. prEN 12822, The European
   Committee for Standardization.
- 788 CEN. 2003. Foodstuffs -Determination of vitamin B1 by high performance liquid chromatography.
   789 prEN 14122, The European Committee for Standardization.

790 CEN. 2006. Foodstuffs -Determination of vitamin B6 by high performance liquid chromatography.

prEN 14164, The European Committee for Standardization.

- Dai, Z., Koh, W.P. 2015. B-Vitamins and Bone Health–A Review of the Current Evidence. Nutrients,
  7, 3322-3346.
- Espe, M., Lemme, A., Petri, A., El-Mowafi, A., 2006. Can Atlantic salmon (*Salmo salar*) grow on diets
  devoid of fish meal? Aquaculture 255, 255-262.
- Espe, M., Lemme A., Petri, A., El-Mowafi, A., Espe, M., Ruohonenm K., El-Mowafi, A. 2012a. Effect
  of taurine supplementation on metabolism and body lipid to protein ratio in juvenile Atlantic
  salmon *Salmo salar*. Aquacult. Res. 43, 349-360
- Espe, M., Ruohonen, K., El-Mowafi, A. 2012b. Dietary FPC reduces the viscera somatic index in ongrowing Atlantic salmon fed diets containing 20% fishmeal inclusion.. Aquacult. Nutr. 18, 599609.
- 802 Espe, M., Andersen, S.M., Holen, E., Rønnestad, I., Veiseth-Kent, E., Zerrahn, J-E., Aksnes, A. 2014.
  803 Methionine deficiency does not increase polyamine turnover through depletion of liver S804 adenosylmethionine (SAM) in juvenile Atlantic salmon. Br. J. Nutr. 112, 1274-1283.
- Espe, M., Andersen, S.M., Veiset-Kent, E., Rønnestad, I., Holen, E., Zerrahn, J.-E., Aksnes, A. 2017.
  Choline supplementation slightly increased lipid gain, but had no impact on growth and protein
  gain, while surplus methionine improved growth due to increased protein accretion without
  affecting lipid deposition. Aquacult. Nutr. 23. 1086-1094.
- Feldsine, P., Abeyta, C., Andrews, W.H., 2002. AOAC International methods committee guidelines
  for validation of qualitative and quantitative food microbiological official methods of analysis.
  J. AOAC Int. 85, 1187–1200.
- Fjelldal, P.G., Hansen, T., Breck, O., Sandvik, R., Waagbø, R., Berg, A. & Ørnsrud, R. 2009.
  Supplementation of dietary minerals during the early seawater phase increase vertebral strength
  and reduce the prevalence of vertebral deformities in fast growing under-yearling Atlantic
  salmon (*Salmo salar* L.) smolt. Aquacult.Nutr. 15, 366–378.
- 816 Gatlin III, D.M., Barrows, F.T., Brown, P., Dabrowski, K., Gaylord, T.G., Hardy, R.W., Herman, E.,
- Hu, G., Krogdahl, A., Nelson, R., Overturf, K., Rust, M., Sealey, W., Skonberg, D., Souza, E.J.,
- Stone, D., Wilson, R., Wurtele, E., 2007. Expanding the utilization of sustainable plant products
  in aquafeeds: A review. Aquacult. Res. 38, 551-579.
- Hamre, K., Waagbø, R., Berge, R.K., Lie, O., 1997. Vitamins C and E interact in juvenile Atlantic
  salmon (*Salmo salar*, L.). Free Radical Biol. Med. 22, 1-2.
- Hamre, K., Sissener, N.H., Lock, E.J., Olsvik, P.A., Espe, M., Torstensen, B.E., Silva, J., Johansen,
  J., Waagbø, R., Hemre, G.I., 2016. Antioxidant nutrition in Atlantic salmon (*Salmo salar*) parr
  and post-smolt, fed diets with high inclusion of plant ingredients and graded levels of
  micronutrients and selected amino acids. PeerJ 4:e2688.

- Hansen, A.-C., Waagbø, R., Hemre, G.-I., 2015. New B vitamin recommendations in fish when fed
  plant-based diets. Aquacult. Nutr. 21, 507-527.
- Hardy, R.W., 2010. Utilization of plant proteins in fish diets: Effects of global demand and supplies
  of fishmeal. Aquacult. Res. 41, 770-776.
- Hemre, G.-I., Sandnes, K., 2008. Seasonal adjusted diets to Atlantic salmon (*Salmo salar*):
  Evaluations of a novel feed based on heat-coagulated fish mince, fed throughout 1 year in sea:
  Feed utilisation, retention of nutrients and health parameters. Aquaculture 274, 166-174.
- 833 Hemre, G.-I., Lock, E.-J., Olsvik, P.A., Hamre, K., Espe, M., Torstensen, B.E., Silva, J., Hansen, A.-
- C., Waagbø, R., Johansen, J.S., Sanden, M., Sissener, N.H. 2016. Atlantic salmon (*Salmo salar*)
  require increased dietary levels of B-vitamins when fed diets with high inclusion of plant based
  ingredients. PeerJ 4:e2493.
- Hevrøy E.M., El-Mowafi, A., Taylor, R., Olsvik, P.A., Norberg, B., Espe, M. 2007. Lysine intake
  affects gene expression of anabolic hormones in Atlantic salmon, *Salmo salar*. General and
  Comparative Endocrinology, 152, 39-46.
- Hoar, W.S., 1988. The physiology of smolting salmonids. In: Hoar, W.S., Randall, D.J. (Eds.), Fish
  Physiology, vol. 11B. Academic Press, London, 275–343.
- Julshamn, K., Brenna, J., Holland, R., Tanner, S., 1999. Plasma source mass spectrometry- New
  developments and applications. Roy. Soc. Chem. 241, 167-172.
- Kadri., S., Metcalfe, N.B., Huntingford, F.A., Thorpe, J.E. 1997. Early morphological predictors of
  maturity in one-sea-winter Atlantic salmon. Aquacult. Int. 5, 41-50.
- Kanehisa M, Goto S., 2000. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acid Res.
  28, 27-30.
- Kortner, T.M., Björkhem, I., Krasnov, A., Timmerhaus, G., Krogahl, A., 2014. Dietary cholesterol
  supplementation to a plant-based diet suppresses the complete pathway of cholesterol synthesis
  and induces bile acid production in Atlantic salmon (*Salmo salar* L.). Br. J. Nutr. 111, 20892103.
- Krossøy, C., Waagbø, R., Fjelldal, P.G., Wargelius, A., Lock, E.J., Graff, I.E, Ørnsrud, R. 2009.
  Dietary menadione nicotinamide bisulphite (vitamin K3) does not affect growth or bone health in first feeding fry of Atlantic salmon (*Salmo salar* L). Aquac. Nutr., 15, 638–649.
- Krossøy, C., Lock, E.-J., Ørnsrud, R., 2011. Vitamin K-dependent γ-glutamylcarboxylase in Atlantic
  salmon (*Salmo salar* L.). Fish Physiol. Biochem. 36, 627-635.
- Lall, S.P., Lewis-McCrea, L.M., 2007. Role of nutrients in skeletal metabolism and pathology in fish
  an overview. Aquaculture 267, 3-19.

- 859 Mæland, A., Rosenlund, G., Stoss, J., Waagbø, R. 1999. Weaning of Atlantic halibut (*Hippoglossus* 860 hippoglossus L.) using formulated diets with various levels of ascorbic acid. Aquacult. Nutr. 5, 861 211-219.
- 862 Mæland, A., Rønnestad, I., Fyhn, H.J., Berg, L., Waagbø, R. 2000. Water-soluble vitamins in natural 863 plankton (copepods) during two consecutive spring blooms compared to vitamins in Artemia 864 franciscana nauplii and metanauplii. Mar. Biol. 136, 765–772.
- 865 Maage, A., Julshamn, K. 1993. Assessment of zinc status in juvenile Atlantic salmon (Salmo salar) 866 by measurement of whole body and tissue levels of zinc. Aquaculture 117, 179-191.
- 867 Mannack, L.V.J.C., Lane, J.D. 2014. The autophagosome: current understanding of formation and 868 maturation. Res. Rep. Biochem. 2015, 39-58.
- 869 National Research Council (NRC), 2011. Nutrient Requirements of Fish and Shrimp. The National 870 Academies Press, Washington DC.
- Menoyo, D., Lopez-Bote, C.J., Diez, A., Obach, A., Bautista, J.M., 2007. Impact of n 3 fatty acid 871 872 chain length and n - 3/n - 6 ratio in Atlantic salmon (Salmo salar) diets. Aquaculture 267, 248-873 259.
- 874 Morais, S., Taggart, J.B., Guy, D.R., Bell, J.G., Tocher, D.R. 2012. Hepatic transcriptome analysis 875 of inter-family variability in flesh n-3 long-chain polyunsaturated fatty acid content in Atlantic 876 salmon. BMC Genomics 13, 410.
- 877 Moren, M., Opstad, I., Hamre, K. 2004. A comparison of retinol, retinal and retinyl ester 878 concentrations in larvae of Atlantic halibut (Hippoglossus hippoglossus L.) fed Artemia or 879 zooplankton. Aquacult. Nutr.10, 253-259.
- 880 Mundheim, H., Aksnes, A., Hope, B. 2004. Growth, feed efficiency and digestibility in salmon 881 (Salmo salar L.) fed different dietary proportions of vegetable protein sources in combination 882 with two fish meal qualities. Aquaculture 237, 315-331.
- Olsvik, P.A., Hemre, G.-I., Waagbø, R. 2013. Exploring early micronutrient deficiencies in rainbow 883 884 trout (Oncorhynchus mykiss) by next-generation sequencing technology - from black box to 885 functional genomics. PLoS ONE 11, e0156668.
- 886 Opstvedt, J., Aksnes, A., Hope, B., Pike, I.H. 2003. Efficiency of feed utilization in Atlantic salmon 887 (Salmo salar L.) fed diets with increasing substitution of fish meal with vegetable proteins. 888 Aquaculture 221, 365-379.
- 889 Ørnsrud, R., Graff, I.E., Høie, S., Totland, G.K., Hemre, G.I. 2002. Hypervitaminosis A in first-890 feeding fry of the Atlantic salmon (Salmo salar L.). Aquacult. Nutr. 8, 7-13.
- 891 Ørnsrud, R., Lock, E.-J., Waagbø, R., Krossøy, C., Fjelldal, P.-G. 2013. Establishing an upper level 892 of intake for vitamin A in Atlantic salmon (Salmo salar L.) postsmolts. Aquacult. Nutr. 19, 651-893

664.

- Oxley, A., Tocher, D.R., Torstensen, B.E., Olsen, R.E. 2005. Fatty acid utilisation and metabolism
  in caecal enterocytes of rainbow trout (*Oncorhynchus mykiss*) fed dietary fish or copepod oil.
  Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1737, 119-129.
- Pfaffl, M.W., 2001. A new mathematical model for relative quantification in real-time RT-PCR.
  Nucleic Acids Res. 29, e45.
- Pietschmann, N., Rijntjes, E., Hoeg, A., Stoedter, M., Schweizer, U., Seemann, P., Schomburg, L.
  2014. Selenoprotein P is the essential selenium transporter for bones. Metallomics, 6, 1043-1049.
- 901 Prabhu, A.J.P., Schrama, J.W., Kaushik, S.J. 2016. Mineral requirements of fish: a systematic review.
  902 Rev. Aquacult. 8, 172-219.
- 903 Prabhu, A.J.P., Schrama, J., Fontagné Dicharry, S., Mariojouls, C., Surget, A., Bueno, M., Geurden,
- 904 I., Kaushik, S.J. 2018. Evaluating dietary supply of microminerals as a premix in a complete
- 905 plant ingredient based diet to juvenile rainbow trout (*Oncorhynchus mykiss*). Aquacult. Nutr.
- 906 24, 539-547.
- Prabhu, A.J.P., Lock, E.-J., Hemre, G.-I., Hamre, K., Espe, M., Olsvik, P.A., Silva, J., Hansen, A.C., Johansen, J., Sissener, N.H., Waagbø, R. 2019a. Recommendations for dietary level of microminerals and vitamin D3 to Atlantic salmon (*Salmo salar*) part and post-smolt when fed low fish
  meal diets. PeerJ 7:e6996.
- Prabhu, A.J.P., Silva, M.S., Kröeckel, S., Holme, M.-H., Ørnsrud, R., Amlund, H., Lock, E.-J.,
  Waagbø, R. 2019b. Effect of levels and sources of dietary manganese on growth and mineral
  composition of post-smolt Atlantic salmon fed low fish meal, plant-based ingredient diets.
  Aquaculture 512, 734287.
- Pratoomyot, J., Bendiksen, E.Å, Bell, J.G., Tocher, D.R. 2008. Comparison of effects of vegetable
  oils blended with southern hemisphere fish oil and decontaminated northern hemisphere fish oil
  on growth performance, composition and gene expression in Atlantic salmon (*Salmo salar* L.).
  Aquaculture 280, 170-178
- Remø, S., Hevrøy, E.M., Olsvik, P.A., Fontanillas, R., Breck, O., Waagbø, R. 2014. Dietary histidine
  requirement to reduce the risk and severity of cataracts is higher than the requirement for growth
  in Atlantic salmon smolts, independently of the dietary lipid source. Br. J. Nutr. 111, 1759-1772.
- 922 Seierstad, S.L., Poppe, T.T., Koppang, E.O., Svindland, A., Rosenlund, G., Frøyland, L., Larsen, S.,
- 923 2005. Influence of dietary lipid composition on cardiac pathology in farmed Atlantic salmon,
  924 Salmo salar L. J. Fish Dis. 28, 677-690.
- Seierstad, S.L., Haugland, Ø, Larsen, S., Waagbø, R., Evensen, Ø. 2009. Pro-inflammatory cytokine
  expression and respiratory burst activity following replacement of fish oil with rapeseed oil in
  the feed for Atlantic salmon (*Salmo salar* L.). Aquaculture 289, 212-218.

- Shearer, K., Åsgård, T, Andorsdottir, G., Aas, G. 1994. Whole body elemental and proximate
  composition of Atlantic salmon (*Salmo salar*) during the life cycle. J. Fish Biol. 44, 785–797.
- 930 Shepherd C.J., Jackson. A.J. 2013. Global fishmeal and fish oil supply: inputs, outputs and markets.
- 931 J. Fish Biol. 83, 1046–1066.
- Sissener, N.H., Julshamn, K., Espe, M., Lunestad, B.T., Hemre, G.-I., Waagbø, R., Måge, A. 2013.
  Surveillance of selected nutrients, additives and undesirables in commercial Norwegian fish
  feeds in the years 2000-2010. Aquacult. Nutr. 19, 555-572.
- Taylor, J.F., Vera, L.M., De Santis, C., Lock, E.-J., Espe, M., Skjaerven, K.H., Leeming, D., del Pozo,
  J., Mota-Velasco, J., Migaud, H., Hamre, K., Tocher, D.R. 2019. The effect of micronutrient
  supplementation on growth and hepatic metabolism in diploid and triploid Atlantic salmon
  (*Salmo salar*) parr fed a low marine ingredient diet. Comp. Biochem. Physiol. B 227, 106-121.
- Torstensen, B.E., Lie Ø., Frøyland, L. 2000. Lipid metabolism and tissue composition in Atlantic
  salmon (*Salmo salar* L.) effects of capelin oil, palm oil, and oleic acid-enriched sunflower oil
  as dietary lipid sources. Lipids 35, 653-664.
- 942 Torstensen, B.E., Bell, J.G., Rosenlund, G., Henderson, R.J., Graff, I.E., Tocher, D.R., Lie, Ø,
  943 Sargent, J.R. 2005. Tailoring of Atlantic salmon (*Salmo salar* L.) flesh lipid composition and
  944 sensory quality by replacing fish oil with a vegetable oil blend. J. Agric. Food Chem. 53, 10166945 10178.
- Turchini, G.M., Francis, D.S., Senadheera, S.P.S.D., Thanuthong, T., De Silva, S.S. 2011. Fish oil
  replacement with different vegetable oils in Murray cod: Evidence of an "omega-3 sparing effect"
  by other dietary fatty acids. Aquaculture 315, 250-259.
- 949 Untergasser, A., Cutcutache, I., Koressaar, T., Ye, J., Faircloth, B.C., Remm, M., Rozen, S.G. 2012.
  950 Primer3-new capabilities and interfaces. Nucleic Acids Res. 40, e115.
- Valente, L.P.M., Bower, N.I., Johnston, I.A. 2012. Postprandial expression of growth-related genes
  in Atlantic salmon (*Salmo salar* L) juveniles fasted for 1 week and fed a single meal to satiation.
  Br. J. Nutr., 108, 2148-2157
- Vera, L.M., Lock, E.-J., Hamre, K., Migaud, H., Leeming, D., Tocher, D.R., Taylor, J.F. 2019.
  Enhanced micronutrient supplementation in low marine diets reduced vertebral malformation in
  diploid and triploid Atlantic salmon (*Salmo salar*) parr, and increased vertebral expression of
  bone biomarker genes in diploids. Comp. Biochem. Physiol. B. 237, 110327.
- Waagbø, R. 2008. Reducing production-related diseases in farmed fish. In: Improving Farmed Fish
  Quality and Safety. Woodhead Publishing Ltd. 363-398.
- Waagbø, R. 2006. Feeding and disease resistance in fish. In: Biology of Nutrition in Growing
  Animals. Elsevier. (Eds. Mosenthin, R., Zentek, J., Żebrowska, T.) 387-415.

- Waagbø, R., Glette, J., Raa-Nilsen, E., Sandnes, K. 1993. Dietary vitamin C, immunity and disease
  resistance in Atlantic salmon (*Salmo salar*). Fish Physiol. Biochem. 12, 61-73.
- Waagbø, R., Berntssen, M.H.G., Danielsen, T., Helberg, H., Kleppa, A.L., Berg Lea, T., Rosenlund,
  G., Tvenning, L., Susort, S., Vikeså, V., Breck, O. 2013. Feeding Atlantic salmon diets with plant
  ingredients during the seawater phase a full-scale net production of marine protein with focus
  on biological performance, welfare, product quality and safety. Aquacult. Nutr. 19, 598-618.
- 968 Watanabe, T., Kiron, V., Satoh, S. 1997. Trace minerals in fish nutrition. Aquaculture 151, 185-207.
- 969 Witten. P. E., Gil-Martens. L., Huysseune. A., Takle. H., Hjelde. K. 2009. Towards a classification
- and an understanding of developmental relationships of vertebral body malformations in Atlantic
  salmon (*Salmo salar* L.). Aquaculture 295, 6–14.
- 972 Ytrestøyl, T., Aas, T.S., Åsgård, T. 2015. Utilisation of feed resources in production of Atlantic
  973 salmon (*Salmo salar*) in Norway. Aquaculture 448, 365-374.
- 974 Zhang, Z., Zhang, J. Xiao, J. 2014. Selenoproteins and selenium status in bone physiology and
- pathology Biochim. Biophys. Acta. 1840, 3246–3256

976 Figure Legends

**Figure 1.** Evolution of growth (increase in weight) though freshwater and seawater phases of Atlantic salmon fed the three experimental diets (mean  $\pm$  SD, n=3). The feeding period for each dietary formulation (% FM/FO) is shown in the blocks at the top of the figure. Superscripts denote significant differences between diets at each respective time point.

981

**Figure 2.** Percentage fish showing at least one or more radiological spinal deformities ( $\geq$ +1dV) recorded at smolt (solid bars) and harvest (hatched bars) in the dietary treatments (25 fish per tank / pen, mean ± SD, n=3). Superscripts denote significant differences between life stage and diet (Kruskall-Wallis, p < 0.05).

986

Figure 3. Functional categories of genes differentially expressed in liver of Atlantic salmon fed diets
L2 (A) and L3 (B) compared to fish fed diet L1. Non-annotated genes and features corresponding to
the same gene are not represented.

990

Figure 4. KEGG pathway analysis of genes belonging to the metabolism category in liver of Atlantic salmon fed diets L2 (A) and L3 (B) compared to fish fed diet L1. Bars represent number of up- and down-regulated genes. Different colours indicate different nutrient groups.

994

**Table 1.** Formulation of the diets in terms of FM and FO inclusions used during the course of the study
 study

Pellet Size	Fish Size	L1	L2	L3	
2.0	20.75~	FM-15%	FM-15%	FM-15%	
2.0 mm	20-75g	FO-8%	FO-8%	FO-8%	ΓW
25	75.250	FM-15%	FM-15%	FM-15%	٦
3.5 mm	75-250g	FO-5%	FO-5%	FO-5%	
50/70	250 1000-	FM-10%	FM-10%	FM-10%	SW
5.0 / 7.0 mm	250-1000g	FO-4%	FO-4%	FO-4%	
0.0	1000 2500	FM-5%	FM-5%	FM-5%	
9.0 mm	1000-2500g	FO-3%	FO-3%	FO-3%	

1001 Table 2. Raw material formulation (g.100g diet<sup>-1</sup>) and proximate composition (analysed) of

1002 experimental diets. ARRAINA Nutrient Package and Amino Acid Premix inclusion for L1/L2/L3

1003 diets respectively.

	MARINE PELLET SIZE (mm)				
INGREDIENTS	3.5	5.0 / 7.0	9.0		
Fish Meal <sup>1</sup>	13.00	8.00	3.00		
Krill Meal <sup>2</sup>	2.00	2.00	2.00		
Soy Protein Concentrate <sup>3</sup>	15.58	15.40	12.58		
Wheat Gluten <sup>4</sup>	12.46	13.09	10.70		
Maize Gluten	3.12	3.08	2.52		
Pea Protein Concentrate <sup>5</sup>	12.46	13.09	10.70		
Wheat <sup>6</sup>	17.86	10.00	13.33		
Sunflower Expeller	-	6.32	6.77		
Fish Oil <sup>7</sup>	5.00	4.00	3.00		
Rapeseed oil <sup>4</sup>	7.65	10.61	16.17		
Linseed oil	1.91	2.55	3.84		
Palm kernel oil	4.78	6.38	9.61		
ARRAINA Nutrient Package <sup>8</sup> †‡	0.75 / 1.50 / 3.00	0.75 / 1.50 / 3.00	0.75 / 1.50 / 3.00		
Monosodium Phosphate	2.03	-	-		
Monocalcium phosphate	-	2.05	1.46		
Amino acid Premix <sup>9,*</sup>	2.14 / 2.34 / 2.32	2.07 / 2.11 / 2.16	2.15 / 2.18 / 2.24		
Yttrium	0.05	0.05	0.05		
Lucantin Pink	0.06	0.06	0.06		
Water change	-1.98	-0.52	0.28		
Proximate Composition (Analysed)					
Moisture (%)	5.6	7.2	6.7		
Crude lipid (%)	24.6	25.7	31.5		
Crude protein (%)	43.8	41.4	41.2		
Ash (%)	6.0	5.3	5.3		
Energy (MJ / kg)	23.2	23.9	25.4		
	2	2~			

<sup>1</sup>Feed Services, Bremen, Germany; <sup>2</sup>Aker Biomarine, Norway; <sup>3</sup>Caramuru, Brazil; <sup>4</sup>Cargill, Germany; <sup>5</sup>Agrident, Germany; <sup>6</sup>WN Lindsey, UK; <sup>7</sup>ED & F Man, Germany; <sup>8</sup>DSM, Netherlands;
<sup>9</sup>Evonik, Germany; <sup>†</sup>Added as components of the nutrient package (NP), and times requirement based on NRC (2011) minimum requirement for Atlantic salmon and modified according to Hamre et al., (2016), diet L1 achieving assumed 100 % minimum requirement; <sup>‡</sup> NP \*Balanced for lysine, methionine, threonine and valine. Contains antioxidant.

1010

**Table 3.** Analysed micronutrient contents (mg.kg<sup>-1</sup>) within the nutrient package (NP): selected

1013 amino acids (histidine and taurine), minerals, vitamins and cholesterol. \* Footnote denotes vitamin

1014 and mineral sources.

		NP	
PREMIX INGREDIENTS	100%	200%	400%
Vitamin A	3.79	7.58	15.16
Vitamin D3	0.05	0.10	0.20
Vitamin E	102.44	204.88	409.76
Vitamin K3	9.82	19.64	39.28
Thiamine	2.67	5.34	10.68
Riboflavin	8.30	16.60	33.20
B6	4.77	9.54	19.08
B12	0.25	0.50	1.00
Niacin	24.80	49.60	99.20
Pantothenic Acid	17.15	34.30	68.60
Folic Acid	2.82	5.64	11.28
Biotin	0.14	0.28	0.56
Vitamin C	80	160	320
Calcium	0.4	0.8	1.6
Cobalt	0.94	1.88	3.76
Iodine	0.67	1.34	2.68
Selenium	0.23	0.46	0.92
Iron	32.64	65.28	130.56
Manganese	12.03	24.06	48.12
Copper	3.24	6.48	12.96
Zinc	66.92	133.84	267.68
Taurine	2450	4900	9800
Histidine	1400	2800	5600
Cholesterol	1100	2200	4400

\*Vitamin & Mineral Source: Vit A, Retinyl acetate; Vit D<sub>3</sub>, Cholecalciferol; Vit E, all-rac-alpha-tocopheryl acetate;
Vit K, menadione nicotinamide bisulphite; Thiamine, thiamine mononitrate; Riboflavin, Riboflavin; B6, Vitamin B6 / pyridoxine hydrochloride; B12, cyanocobalamin; Niacin, nicotinic acid; Pantothenic acid, Calcium-D-pantothenate;
Folic acid, Folic acid; Biotin, Biotin; Vit C, L-ascorbic acid; Co: Cobalt carbonate; I, Calcium iodate anhydrous; Se, Sodium selenite; Fe, ferrous sulphate monohydrate; Mn, Manganous oxide; Cu, Cupric sulphate pentahydrate; Zn,

1020 Zinc oxide.

- **Table 4.** Analysed concentrations of selected amino acids (taurine, histidine and methionine g.kg<sup>-1</sup>)
- 1023 macro-minerals (calcium, magnesium and phosphorous, g.kg<sup>-1</sup>) micro-minerals and vitamins
- 1024 (mg.kg<sup>-1</sup>) of the experimental diets. Nutrients added at graded levels to the feeds are shown with an
- asterisk.

		DIET		
	L1	L2	L3	NRC 2011
Vitamin A*	3.7	5.2	12.2	0.75 <sup>a</sup>
Vitamin D3*	0.15	0.19	0.19	0.04 <sup>a</sup>
Vitamin E*	241.5	364.0	436.5	60 <sup>b</sup>
Vitamin K3*	0.71	1.51	2.70	<10 <sup>b</sup>
Thiamin*	4.5	7.1	8.8	1ª,
Riboflavin*	17.2	27.8	33.5	4 <sup>a</sup> ,
Vitamin B6*	12.8	16.8	21.3	5 <sup>b</sup>
Vitamin B12*	0.18	0.35	0.67	NT
Niacin*	73.0	112.0	148.0	10 <sup>a</sup> ,
Pantothenic acid*	24.0	58.0	44.0	20 <sup>a,</sup>
Folic acid*	6.53	9.69	11.67	$1^{a}$
Biotin*	0.51	0.72	0.74	0.15 <sup>a</sup>
Vitamin C*	183.0	251.0	409.0	20 <sup>b</sup>
Cobalt*	0.18	0.22	0.32	NT
Iodine*	n.a	n.a	n.a	1.1 <sup>a</sup>
Selenium*	1.13	1.48	1.65	0.15 <sup>a</sup>
Iron*	330.0	358.0	403.0	30-60 <sup>b</sup>
Manganese*	42.0	53.0	86.0	10 <sup>b</sup>
Copper*	11.8	14.8	22.8	5 <sup>b</sup>
Zinc*	94.0	156.0	330.0	37 <sup>b</sup>
Taurine*	2.6	4.4	10.1	NR <sup>b</sup>
Methionine	9.7	9.9	10.3	7.0 <sup>b</sup>
Histidine*	11.4	13.1	17.1	8.0 <sup>b</sup>
Calcium*	6.7	7.1	8.2	NR <sup>b</sup> *
Magnesium	1.7	1.7	1.7	0.4 <sup>b</sup>
Phosphorus	12.7	12.5	12.5	8.0 <sup>b</sup>
Cholesterol*	n.a	n.a	n.a	NR

1026 ‡Current NRC, 2011 minimum requirement recommendations determined in <sup>a</sup> rainbow trout, <sup>b</sup>

Atlantic salmon are shown for comparison. n.a. not analysed; NR\* no requirement freshwater; NT,not tested.

1030	Table 5. Growth	and morphometric	c indices recorded	at the end of the	e fresh and sea	awater phases of
------	-----------------	------------------	--------------------	-------------------	-----------------	------------------

1031 Atlantic salmon fed low marine ingredient diets (FM 15% / FO 8%) with differing micronutrient

supplementation levels (L1 = 100 %, L2 = 200 % and L3 = 400 % NRC Premix). Superscripts

1033 denote significant differences between diets (mean  $\pm$  SD, n=3, p < 0.05, one-way ANOVA)

1034

		DIET		
	L1	L2	L3	p values
FRESHWATER				
Initial Parr Wt. (g)	$38.2\pm0.6$	$38.0\pm0.6$	$38.1\pm0.5$	0.946
Final Smolt Wt. (g)	$68.0\pm0.5^{\circ}$	$77.4\pm0.5^{a}$	$73.8\pm0.8^{b}$	0.0001
Condition Factor (K)	$1.29\pm0.00^{\rm c}$	$1.19\pm0.00^{b}$	$1.18\pm0.00^{a}$	0.0001
TGC <sub>wt</sub>	$1.29\pm0.01^{\rm c}$	$1.59\pm0.01$ $^a$	$1.48\pm0.02^{\rm b}$	0.0001
bFCR	$0.90\pm0.01^{a}$	$0.71 \pm 0.01^{\circ}$	$0.76\pm0.01^{\rm b}$	0.0001
VSI (%)	$8.23\pm0.10$	$8.21\pm0.18$	$8.44\pm0.35$	0.456
HSI (%)	$1.28\pm0.06^{a}$	$1.04\pm0.01^{b}$	$1.15\pm0.06^{b}$	0.003
Mortality (%)	$0.2 \pm 0.2$	$0.3 \pm 0.1$	$0.0 \pm 0.0$	0.646
SEAWATER				
Final Wt. (g)	$2127.0 \pm 59.0^{b}$	$2381.0\pm82.0^a$	$2385.0\pm37.0^a$	0.041
Condition Factor (K)	$1.37\pm0.01^{b}$	$1.43\pm0.02^{ab}$	$1.46\pm0.03^{a}$	0.049
TGC <sub>wt</sub>	$2.87\pm0.04^{\rm b}$	$2.98\pm0.05^{ab}$	$3.02\pm0.02^{a}$	0.045
bFCR	$1.11 \pm 0.01^{a}$	$1.08\pm0.01^{b}$	$1.08\pm0.01^{\rm b}$	0.049
VSI (%)	$8.66\pm0.10$	$8.98 \pm 0.11$	$8.75\pm0.35$	0.106
HSI (%)	$1.08\pm0.06$	$1.02\pm0.01$	$1.10\pm0.04$	0.426
% Mortality	$0.95\pm0.76$	$2.64 \pm 2.25$	$0.54\pm0.13$	0.594
% Maturation	$9.99 \pm 1.64$	$5.94\pm0.48$	$9.84\pm0.74$	0.063

- **Table 6.** Protein, lipid, ash (g.kg<sup>-1</sup> wet wt.), mineral content (mg.kg<sup>-1</sup> wet wt.), retention (%) in
- 1038 whole body, and protein, lipid and fatty acid composition (%) in muscle (Norwegian Quality Cut,
- 1039 NQC) of Atlantic salmon at end of trial. Superscripts denote significant differences between diets
- 1040 when variances were homogenous (mean  $\pm$  SD, n=3, p<0.05, ANOVA), when non-homogenous

1041	variances:	$(\text{mean} \pm SD,$	n=3, <i>p</i> <	0.5,	, Kruskal-Wallis)
------	------------	------------------------	-----------------	------	-------------------

		DIET		_
_	L1	L2	L3	<i>p</i> values
WHOLE BODY <sup>‡</sup>				
Protein	$16.6\pm0.3$	$16.8 \pm 0.2$	$16.6\pm0.5$	0.61
Lipids	$19.1 \pm 1.4$	$20.0\pm0.7$	$19.7\pm0.8$	0.59
Ash	$1.5\pm0.11^{b}$	$1.5\pm0.11^{b}$	$1.7\pm0.11^{a}$	0.045
Zn	$9.0 \pm 1.0^{\circ}$	$18.0\pm3.0^{b}$	$29.0\pm3.0^{a}$	0.0003
Mn	$1.5 \pm 0.5$	$1.5 \pm 0.3$	$1.3 \pm 0.8$	0.89
Fe	$7.1 \pm 2.5$	$8.1 \pm 0.4$	$8.9\pm1.9$	0.53
Cu	$2.7 \pm 0.1$	$2.8 \pm 0.2$	$2.8 \pm 0.4$	0.81
Se	$0.18\pm0.01^{\text{b}}$	$0.22\pm0.02^{b}$	$0.31\pm0.02^{a}$	0.0003
Mg	$273.0\pm15.0$	$273.0\pm6.0$	$273.0\pm15.0$	1.00
Ca	$2500\pm1000$	$2800\pm400$	$2600 \pm 1700$	0.50
Р	$3000\pm200$	$3400\pm200$	$3400\pm800$	0.94
WHOLE BODY R	ETENTION			
Protein	$37.0\pm1.0$	$37.0\pm1.0$	$37.0\pm2.0$	0.63
Lipids	$62.0\pm5.0$	$68.0\pm2.0$	$67.0\pm2.0$	0.12
Ash	$28.0\pm1.6$	$28.7\pm1.3$	$29.1 \pm 1.4$	0.83
Zn	$8.3\pm0.7$	$11.3\pm2.2$	$7.7 \pm 1.0$	0.18
Mn	$2.8\pm0.9$	$2.6\pm0.6$	$1.3\pm0.8$	0.11
Fe	$1.8\pm0.6$	$1.8\pm0.1$	$2.0 \pm 0.4$	0.77
Cu	$19.7\pm0.5^{a}$	$16.9 \pm 1.0^{ab}$	$10.4 \pm 1.5^{b}$	0.0001
Se	$12.5\pm0.5^{b}$	$12.2\pm1.0^{b}$	$17.9 \pm 1.5^{\rm a}$	0.001
Mg	$14.0\pm1.0$	$14.9\pm0.4$	$15.2\pm1.1$	0.29
Р	$25.0\pm7.0$	$26 \pm 1.0$	$26.0\pm6.0$	1.00
Ca	$38.3\pm23.0$	$33.4\pm6.0$	$27.4 \pm 19.0$	0.92
NQC				
Protein	$19.8\pm0.5$	$20.2\pm0.6$	$20.0\pm0.4$	0.62
Lipid	$13.9\pm0.3^{b}$	$13.5\pm0.1^{b}$	$15.0\pm0.5^{a}$	0.004
Total PUFA	$31.4\pm0.4$	$31.4\pm0.3$	$30.8\pm0.2$	0.40
n-6 LC PUFA	$17.5\pm0.2^{\rm a}$	$17.1\pm0.1^{ab}$	$16.9\pm0.1^{b}$	0.050
n-3 LC PUFA	$13.7\pm0.2$	$14.0\pm0.2$	$13.7\pm0.1$	0.45
EPA	$1.5\pm0.00$	$1.6\pm0.0$	$1.6\pm0.0$	0.056
DHA	$1.82\pm0.05^{ab}$	$1.90\pm0.06^a$	$1.60\pm0.07^{b}$	0.036
Total Carotenoid	$4.27\pm0.17$	$3.87\pm0.29$	$3.96\pm0.33$	0.59

1042 <sup>‡</sup>Initial Body compositions at smolt sea transfer (L1 / L2 / L3):

**1043** Protein: (16.24±0.16 / 16.49±0.19 / 16.7±0.11); Lipids: (11.30±0.24 / 11.8±0.35 / 11.6±0.46); Ash: (2.23±0.12 /

1044 2.25±0.14 / 2.15±0.07); Zn: (25±4.5 / 30±0.2 / 44±4.5); Mn: (2.2±0.2 / 2.1±0.6 / 1.9±0.4); Fe: (10±0.4 / 14±5.9 /

1045 11±0.1); Cu: (1.2±0.1 / 1.4±0.1 / 1.5±0.1); Se: (0.29±0.01 / 0.32±0.02 / 0.37±0.02); Mg: (355±21 / 345±21 / 350±0);

**1046** Ca: (3300±707 / 3050±1061 / 2900±849); P: (4750±354 / 4650±566 / 4600±354).

1048	Table 7. Amino acid retention (%) in Atlantic salmon fed the three plant-based diets. Superscripts
1049	denote significant differences between diets (mean $\pm$ SD, n=3, p<0.05, ANOVA).
1050	

		DIET		
	L1	L2	L3	p values
His	$31.2\pm0.3^{a}$	$30.2\pm0.5^{a}$	$26.8\pm0.9^{b}$	0.005
OH-pro	$87.5\pm10.7$	$75.6 \pm 1.9$	$101.2\pm18.8$	0.41
Arg	$33.0\pm0.4$	$33.4\pm0.3$	$33.4\pm1.4$	0.94
Ser	$31.5\pm0.3$	$32.2\pm0.4$	$32.6\pm1.1$	0.61
Gly	$46.8 \pm 1.1$	$44.4\pm0.7$	$46.5\pm2.6$	0.56
Asp	$43.5 \pm 1.1$	$44.1\pm0.8$	$43.0\pm1.0$	0.74
Glu	$22.7\pm0.2$	$22.8\pm0.5$	$22.1\pm0.9$	0.71
Thr	$42.1\pm0.2$	$43.0\pm0.2$	$42.8\pm1.1$	0.68
Ala	$50.2 \pm 1.1$	$50.6\pm0.2$	$50.5\pm1.4$	0.95
Pro	$20.7\pm0.4$	$20.4\pm0.1$	$20.8\pm0.9$	0.86
Tyr	$36.6\pm0.4$	$37.7\pm0.3$	$36.4 \pm 1.1$	0.55
Met	$43.6\pm0.3$	$44.9\pm0.3$	$42.0\pm1.6$	0.19
Lys	$49.4 \pm 1.4^{a}$	$49.3\pm0.4^{a}$	$45.7\pm0.2^{b}$	0.04
Val	$41.0\pm0.5$	$41.7 \pm 1.1$	$39.4\pm0.7$	0.18
Ile	$38.4\pm0.5$	$39.2 \pm 1.1$	$37.0\pm0.6$	0.21
Leu	$35.5\pm0.1$	$36.0 \pm 0.1$	$35.5\pm0.6$	0.53
Phe	$27.6\pm0.3$	$28.5\pm0.3$	$28.3\pm1.2$	0.71

**Table 8.** Non-protein N metabolites in muscle (µmol.g<sup>-1</sup> wet wt.). Superscripts denote significant

1055 differences between diets (mean  $\pm$  SD, n=3, p<0.05, ANOVA).

		DIET		
	L1	L2	L3	p values
Taurine	$0.94\pm0.01$	$1.13\pm0.22$	$1.00\pm0.02$	0.58
Urea	$0.53\pm0.02$	$0.52\pm0.02$	$0.55\pm0.06$	0.88
Asp	$0.09\pm0.00$	$0.10\pm0.00$	$0.12\pm0.00$	0.15
OH-pro	$0.27\pm0.02^{a}$	$0.25\pm0.01^{ab}$	$0.16\pm0.01^{b}$	0.03
Thr	$0.43\pm0.02$	$0.40\pm0.01$	$0.43\pm0.02$	0.62
Ser	$0.14\pm0.01^{a}$	$0.09\pm0.01^{b}$	$0.06\pm0.01^{b}$	0.0005
Glu	$0.99\pm0.06$	$0.93\pm0.02$	$0.87\pm0.11$	0.51
Gln	$0.14\pm0.02$	$0.23\pm0.03$	$0.20\pm0.02$	0.08
Sarcosine	$0.08\pm0.02$	$0.11\pm0.02$	$0.09\pm0.02$	0.64
Pro	$0.53\pm0.02$	$0.48\pm0.06$	$0.29\pm0.02$	0.06
Gly	$2.37\pm0.10^{a}$	$1.46\pm0.08^{b}$	$0.98\pm0.06^{c}$	0.0006
Ala	$2.83\pm0.08$	$2.78\pm0.11$	$2.47\pm0.12$	0.11
Citruline	$0.03\pm0.01$	$0.03\pm0.00$	$0.03\pm0.00$	0.79
Alpha amino butyric acid	$0.04\pm0.00$	$0.05\pm0.00$	$0.04\pm0.00$	0.22
Val	$0.28\pm0.00$	$0.29\pm0.01$	$0.29\pm0.01$	0.81
Met	$0.10\pm0.00$	$0.11\pm0.00$	$0.10\pm0.00$	0.18
Cystathionine	$0.01\pm0.00$	$0.01\pm0.00$	$0.01\pm0.00$	0.42
Ile	$0.13\pm0.00$	$0.14\pm0.00$	$0.13\pm0.00$	0.73
Leu	$0.23\pm0.01$	$0.25\pm0.01$	$0.24\pm0.01$	0.30
Tyr	$0.17\pm0.02$	$0.23\pm0.03$	$0.18\pm0.02$	0.35
Beta Ala	$0.35\pm0.02$	$0.39\pm0.04$	$0.30\pm0.01$	0.10
Phe	$0.07\pm0.00$	$0.09\pm0.00$	$0.07\pm0.00$	0.05
Ammonia	$4.94\pm0.15$	$4.80\pm0.07$	$4.66\pm0.05$	0.22
Ornithine	$0.02\pm0.00$	$0.01\pm0.00$	$0.01\pm0.00$	0.30
Lys	$0.81\pm0.12$	$0.86\pm0.04$	$0.95\pm0.13$	0.62
1-methyl His	$0.05\pm0.00$	$0.06\pm0.00$	$0.06\pm0.01$	0.42
His	$1.53\pm0.20^{\rm c}$	$2.33\pm0.07^{b}$	$4.10\pm0.09^{a}$	0.0001
Anserine	$26.58\pm0.21$	$27.77\pm0.20$	$27.46\pm0.72$	0.23
Carnosine	$0.37\pm0.05$	$0.57\pm0.08$	$0.42\pm0.05$	0.12
Arg	$0.16\pm0.01$	$0.17\pm0.00$	$0.18\pm0.01$	0.51

**Table 9.** Tissue concentrations (mg.kg<sup>-1</sup> wet wt.) and retention (%) of water soluble vitamins.

1061 Superscripts denote significant differences between diets when variances were homogenous (mean

 $\pm$  SD, n=3, p<0.05, ANOVA), when non-homogenous variances: (mean  $\pm$  SD, n=3, p < 0.5,

1063 Kruskal-Wallis).

		_					
	L1	L2	L3	p values			
WHOLE BODY							
Vitamin C	$45.0\pm4.0^{b}$	$60.0\pm6.0^{\rm a}$	$68.0\pm5.0^{a}$	0.004			
Thiamin	$1.2\pm0.1$	$1.3 \pm 0.1$	$1.2\pm0.1$	0.3			
Riboflavin	$2.3\pm0.1$	$2.4\pm0.21$	$2.3\pm0.2$	0.57			
Pantothenic acid	$9.3\pm0.7^{b}$	$12.0\pm0.0^{a}$	$12.3\pm0.6^a$	<b>6*10</b> <sup>-4</sup>			
Niacin	$32 \pm 3^{c}$	$46\pm2^{b}$	$56\pm4^{a}$	<b>4*10</b> -4			
Folic acid	$0.2\pm0.0$	$0.3\pm0.04$	$0.3\pm0.02$	0.25			
Biotin	$0.1\pm0.0$	$0.2\pm0.2$	$0.1\pm0.01$	0.25			
Vitamin B6	$0.3\pm0.02$	$0.5\pm0.03$	$0.5\pm0.03$	0.05			
LIVER							
Vitamin C	$53.0\pm1.0$	$91\pm28$	$44 \pm 24$	0.06			
Biotin	$2.8\pm0.6$	$2.7\pm0.5$	$3.1\pm0.6$	0.37			
Vitamin B12	$0.6\pm0.0$	$0.5\pm0.1$	$0.6\pm0.1$	0.28			
Folic acid	$16.8\pm0.3$	$14.8 \pm 1.2$	$15.9\pm0.7$	0.06			
Niacin	$70.0\pm3.0$	$72.0\pm6.0$	$79.0\pm12.0$	0.42			
Riboflavine	$12.7\pm0.6$	$12.3\pm0.6$	$12.3\pm0.6$	0.73			
GILL							
Pantothenic acid	$8.5\pm1.3$	$10.9\pm1.9$	$12.0\pm2.1$	0.17			
MUSCLE							
Vitamin B6	$5.8\pm0.2$	$6.9\pm0.8$	$6.9\pm1.0$	0.17			
<b>RETENTION IN WHOLE BODY (%)</b>							
Thiamin	$21.2\pm2.2$	$18.3\pm1.0$	$18.6\pm1.0$	0.113			
Riboflavin	$9.8\pm0.1$	$7.1\pm0.5$	$6.5\pm0.5$	0.051			
Niacin	$37.4\pm3.3$	$39.2\pm2.8$	$33.1\pm2.2$	0.079			
Biotin	$11.4\pm0.0$	$9.0\pm0.3$	$10.1\pm1.5$	0.148			
Folic acid	$3.5 \pm 0.1$	$2.3\pm0.4$	$1.6 \pm 0.1$	0.027			

- **Table 10.** Tissue concentrations (mg.kg<sup>-1</sup> wet wt.) and retention (%) of lipid soluble vitamins.
- 1071 Superscripts denote significant differences between diets when variances were homogenous
- 1072 (p<0.05, ANOVA), when non-homogenous variances: (p < 0.5, Kruskal-Wallis) (mean  $\pm$  SD, n=3
- 1073 tanks).
- 1074
- 1075

	DIET					
	L1	L2	L3	p value		
WHOLE BODY						
Dry matter %	$41.0\pm1.0$	$40.0\pm1.0$	$41.0\pm1.0$	0.40		
Vitamin A <sub>1</sub>	$0.20\pm0.16$	$0.58\pm0.13$	$2.23\pm0.42$	0.04		
Vitamin A <sub>2</sub>	$0.39\pm0.06^{c}$	$0.83\pm0.12^{b}$	$1.77\pm0.25^{\rm a}$	0.0001		
Vitamin K (K <sub>1</sub> )	$30.0\pm6.0$	$32.0\pm1.0$	$30.0\pm0.0$	0.25		
Vitamin K (MK <sub>4</sub> )	$73.0\pm6.0^{b}$	$84.0\pm8.0^{ab}$	$100.0 \pm 7.0^{a}$	0.008		
Vitamin E (α-TOH)	$28.0\pm5.0^{\rm c}$	$41.0\pm5.0^{\:b}$	$57.0 \pm 2.0^{a}$	0.0005		
Vitamin E (y-TOH)	$12.5\pm3.8$	$12.1 \pm 1.4$	$11.1\pm0.5$	0.56		
MUSCLE						
Vitamin D <sub>3</sub>	$0.023\pm0.006^{c}$	$0.030 \pm 0.000^{b}$	$0.043 \pm 0.006^{a}$	0.01		
Vitamin E (α-TOH)	$17 \pm 2^{c}$	$24 \pm 1^{b}$	$36 \pm 3^a$	0.0001		
Vitamin E (y -TOH)	$9.9 \pm 1.7$	$9.8\pm0.8$	$9.2\pm0.5$	ns		
WHOLE BODY RETENTION						
Vitamin E (α-TOH)	$8.8 \pm 1.7^{a}$	$9.2\pm0.9^{ab}$	$11.8\pm0.6^{\rm b}$	0.03		
Vitamin E (γ -TOH)	$34.0\pm10.0$	$30.0\pm3.0$	$30.0\pm1.0$	0.60		

1076

1077

- **Table 11.** Relative expression of diets L2 and L3 to L1 for genes involved in lipid and fatty acid
- 1080 (FA) metabolism (liver) and protein turnover (muscle) in Atlantic salmon fed the experimental diets
- 1081 (mean ± SEM, n=3). Superscripts denote significant differences between diets.

GENE         L1         L2         L3         p           Value           LIPID AND FA METABOLISM (Liver)           Apolipoprotein B-100 (apoB) $1.00 \pm 0.09$ $1.68 \pm 0.10$ $1.68 \pm 0.31$ $0.890$ Acetyl-CoA carboxylase (acc) $1.00 \pm 0.13$ $1.16 \pm 0.22$ $1.23 \pm 0.18$ $0.520$ Cholesterol 7 alpha-hydroxylase (Cyp7a1) $1.00 \pm 0.40$ $0.64 \pm 0.15$ $1.14 \pm 0.55$ $0.572$ Fatty acyl elongase 2 (elovl2) $1.00 \pm 0.07$ $1.07 \pm 0.14$ $0.84 \pm 0.16$ $0.454$ Fatty acyl elongase 6 (elovl6) $1.00 \pm 0.50$ $1.17 \pm 0.78$ $0.91 \pm 0.39$ $0.577$ Delta-6 fatty acyl desaturase isoform a (fads2d6a) $1.00 \pm 0.34^a$ $0.36 \pm 0.09^b$ $0.44 \pm$ $0.035$ S-acyl fatty acid synthase thioesterase (fas) $1.00 \pm 0.14$ $0.90 \pm 0.09$ $1.00 \pm 0.13$ $0.59 \pm 0.13$ $0.86 \pm 0.26$ $0.854$ Betaine-homocysteine S-methyltransferase (bhmt) $1.00 \pm 0.13$ $0.91 \pm 0.31$ $0.90 \pm 0.13$ $0.520$ Cystathionine-denosyltransferase (mat1) $1.00 \pm 0.20$ $0.74 \pm 0.45$ $0.94 \pm 0.17$ $0.640$ <th></th> <th>_</th> <th>DIET</th> <th></th> <th>_</th>		_	DIET		_				
value	GENE	L1	L2	L3	p				
LIPID AND FA METABOLISM (Liver)         Apolipoprotein B-100 (apoB) $1.00 \pm 0.09$ $1.68 \pm 0.10$ $1.68 \pm 0.31$ $0.890$ Acetyl-CoA carboxylase (acc) $1.00 \pm 0.13$ $1.16 \pm 0.22$ $1.23 \pm 0.18$ $0.520$ Cholesterol 7 alpha-hydroxylase (Cyp7a1) $1.00 \pm 0.40$ $0.64 \pm 0.15$ $1.14 \pm 0.55$ $0.572$ Fatty acyl elongase 2 (elovl2) $1.00 \pm 0.07$ $1.07 \pm 0.14$ $0.84 \pm 0.16$ $0.454$ Fatty acyl elongase 6 (elovl6) $1.00 \pm 0.07$ $1.07 \pm 0.14$ $0.84 \pm 0.16$ $0.454$ Fatty acyl elongase 6 (elovl6) $1.00 \pm 0.50$ $1.17 \pm 0.78$ $0.91 \pm 0.39$ $0.577$ Delta-6 fatty acyl desaturase isoform a (fads2d6a) $1.00 \pm 0.34^a$ $0.36 \pm 0.09^b$ $0.44 \pm$ $0.035$ S-acyl fatty acid synthase thioesterase (fas) $1.00 \pm 0.14$ $0.90 \pm 0.09$ $1.00 \pm 0.10$ $0.671$ I-CARBON METABOLISM (Liver)       I.00 \pm 0.26 $0.91 \pm 0.31$ $0.86 \pm 0.26$ $0.854$ Betaine-homocysteine S-methyltransferase ( <i>hhmt</i> ) $1.00 \pm 0.13$ $0.91 \pm 0.13$ $0.99 \pm 0.13$ $0.524$ Growth hormone receptor (ghr) $1.00 \pm 0.20$ $0.74 \pm 0.45$ $0.94 \pm 0.17$					value				
Apolipoprotein B-100 (apoB) $1.00 \pm 0.09$ $1.68 \pm 0.10$ $1.68 \pm 0.31$ $0.890$ Acetyl-CoA carboxylase (acc) $1.00 \pm 0.13$ $1.16 \pm 0.22$ $1.23 \pm 0.18$ $0.520$ Cholesterol 7 alpha-hydroxylase (Cyp7a1) $1.00 \pm 0.40$ $0.64 \pm 0.15$ $1.14 \pm 0.55$ $0.572$ Fatty acyl elongase 2 (elovl2) $1.00 \pm 0.07$ $1.07 \pm 0.14$ $0.84 \pm 0.16$ $0.454 \pm 0.15$ Fatty acyl elongase 5 isoform b (elovl5) $1.00 \pm 0.07$ $1.07 \pm 0.14$ $0.84 \pm 0.16$ $0.454 \pm 0.15$ Fatty acyl elongase 6 (elovl6) $1.00 \pm 0.07$ $1.07 \pm 0.14$ $0.84 \pm 0.16$ $0.454 \pm 0.15$ S-acyl fatty acyl desaturase isoform a (fads2d6a) $1.00 \pm 0.34^a$ $0.36 \pm 0.09^b$ $0.44 \pm 0.16$ $0.12^{ab}$ S-acyl fatty acid synthase thioesterase (fas) $1.00 \pm 0.26$ $0.91 \pm 0.31$ $0.86 \pm 0.26$ $0.854$ Betaine-homocysteine S-methyltransferase (bhmt) $1.00 \pm 0.13$ $0.91 \pm 0.13$ $0.90 \pm 0.13$ $0.271$ Growth hormone receptor (ghr) $1.00 \pm 0.20$ $0.74 \pm 0.45$ $0.94 \pm 0.17$ $0.640$ Interleukin 8 (il8) $1.00 \pm 0.20$ $1.10 \pm 0.13$ $0.92 \pm 0.079$ $0.023$ Intef	LIPID AND FA METABOLISM (Liver)								
Acetyl-CoA carboxylase (acc) $1.00 \pm 0.13$ $1.16 \pm 0.22$ $1.23 \pm 0.18$ $0.502$ Cholesterol 7 alpha-hydroxylase (Cyp7a1) $1.00 \pm 0.40$ $0.64 \pm 0.15$ $1.14 \pm 0.55$ $0.572$ Fatty acyl elongase 2 (elovl2) $1.00 \pm 0.40$ $0.64 \pm 0.15$ $1.14 \pm 0.55$ $0.572$ Fatty acyl elongase 5 isoform b (elovl5) $1.00 \pm 0.07$ $1.07 \pm 0.14$ $0.84 \pm 0.16$ $0.454$ Fatty acyl elongase 6 (elovl6) $1.00 \pm 0.30$ $1.17 \pm 0.78$ $0.91 \pm 0.39$ $0.577$ Delta-6 fatty acyl desaturase isoform a (fads2d6a) $1.00 \pm 0.14$ $0.90 \pm 0.09^{b}$ $0.44 \pm$ $0.035$ S-acyl fatty acid synthase thioesterase (fas) $1.00 \pm 0.14$ $0.90 \pm 0.09$ $1.00 \pm 0.10$ $0.671$ I-CARBON METABOLISM (Liver)       I.00 \pm 0.26 $0.91 \pm 0.31$ $0.86 \pm 0.26$ $0.854$ Betaine-homocysteine S-methyltransferase ( <i>hmt</i> ) $1.00 \pm 0.13$ $0.91 \pm 0.13$ $1.09 \pm 0.13$ $0.271$ Growth hormone receptor (ghr) $1.00 \pm 0.20$ $0.74 \pm 0.16$ $0.94 \pm 0.17$ $0.640$ Interleukin 8 (il8) $1.00 \pm 0.20$ $1.10 \pm 0.17$ $1.14 \pm 0.12$ $0.663$ PROTEIN TURNOVER (Muscle)	Apolipoprotein B-100 (apoB)	$1.00 \pm 0.09$	$1.68 \pm 0.10$	$1.68 \pm 0.31$	0.890				
Cholesterol 7 alpha-hydroxylase (Cyp7a1) $1.00 \pm 0.40$ $0.64 \pm 0.15$ $1.14 \pm 0.55$ $0.572$ Fatty acyl elongase 2 (elovl2) $1.00 \pm 0.26^{ab}$ $0.56 \pm 0.15^{b}$ $0.32$ Fatty acyl elongase 5 isoform b (elovl5) $1.00 \pm 0.07$ $1.07 \pm 0.14$ $0.84 \pm 0.16$ $0.454$ Fatty acyl elongase 6 (elovl6) $1.00 \pm 0.50$ $1.17 \pm 0.78$ $0.91 \pm 0.39$ $0.577$ Delta-6 fatty acyl desaturase isoform a (fads2d6a) $1.00 \pm 0.34^{a}$ $0.36 \pm 0.09^{b}$ $0.44 \pm 0.035$ $0.12^{ab}$ S-acyl fatty acid synthase thioesterase (fas) $1.00 \pm 0.26$ $0.91 \pm 0.31$ $0.86 \pm 0.26$ $0.854$ Betaine-homocysteine S-methyltransferase (bhmt) $1.00 \pm 0.26$ $0.91 \pm 0.31$ $0.86 \pm 0.26$ $0.854$ Betaine-homocysteine S-methyltransferase (bhmt) $1.00 \pm 0.13$ $0.91 \pm 0.13$ $1.09 \pm 0.13$ $0.271$ Growth hormone receptor (ghr) $1.00 \pm 0.20$ $0.74 \pm 0.15$ $1.10 \pm 0.13$ $0.271$ Interleukin 1 beta (illb) $1.00 \pm 0.20$ $0.74 \pm 0.45$ $0.94 \pm 0.17$ $0.640$ Interleukin 1 beta (illb) $1.00 \pm 0.09$ $1.28 \pm 0.20$ $1.24 \pm 0.11$ $0.441$ Mutophagy-related 1	Acetyl-CoA carboxylase (acc)	$1.00 \pm 0.13$	$1.16 \pm 0.22$	$1.23 \pm 0.18$	0.520				
Fatty acyl elongase 2 (elovl2)       1.00 ±       1.19 ± 0.20 <sup>a</sup> 0.56 ± 0.15 <sup>b</sup> 0.032         Fatty acyl elongase 5 isoform b (elovl5)       1.00 ± 0.07       1.07 ± 0.14       0.84 ± 0.16       0.454         Fatty acyl elongase 6 (elovl6)       1.00 ± 0.07       1.07 ± 0.14       0.84 ± 0.16       0.454         Delta-6 fatty acyl desaturase isoform a (fads2d6a)       1.00 ± 0.50       1.17 ± 0.78       0.91 ± 0.31       0.84 ± 0.16       0.454 ±         S-acyl fatty acyl desaturase isoform a (fads2d6a)       1.00 ± 0.14       0.99 ± 0.09       1.00 ± 0.31       0.44 ± 0.035         S-acyl fatty acid synthase thioesterase (fas)       1.00 ± 0.26       0.91 ± 0.31       0.86 ± 0.26       0.854         Bataine-homocysteine S-methyltransferase (bhmt)       1.00 ± 0.26       0.91 ± 0.31       1.09 ± 0.13       0.027 ±         Growth hormone receptor (ghr)       1.00 ± 0.20       0.74 ± 0.15       0.104 ± 0.13       0.94 ± 0.17       0.663         IMMUNE FUNCTION	Cholesterol 7 alpha-hydroxylase (Cyp7a1)	$1.00 \pm 0.40$	$0.64 \pm 0.15$	$1.14 \pm 0.55$	0.572				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Fatty acyl elongase 2 ( <i>elovl2</i> )	$1.00 \pm$	$1.19 \pm 0.20^{a}$	$0.56\pm0.15^{\mathrm{b}}$	0.032				
Fatty acyl elongase 5 isoform b (elovl5) $1.00 \pm 0.07$ $1.07 \pm 0.14$ $0.84 \pm 0.16$ $0.454$ Fatty acyl elongase 6 (elovl6) $1.00 \pm 0.50$ $1.17 \pm 0.78$ $0.91 \pm 0.39$ $0.577$ Delta-6 fatty acyl desaturase isoform a (fads2d6a) $1.00 \pm 0.34^a$ $0.36 \pm 0.09^b$ $0.44 \pm$ $0.035$ S-acyl fatty acid synthase thioesterase (fas) $1.00 \pm 0.14$ $0.90 \pm 0.09$ $1.00 \pm 0.10$ $0.671$ <b>1-CARBON METABOLISM (Liver)</b> $Cystathionine-g-synthase (cbs)$ $1.00 \pm 0.26$ $0.91 \pm 0.31$ $0.86 \pm 0.26$ $0.854$ Betaine-homocysteine S-methyltransferase (bhmt) $1.00 \pm 0.13$ $0.91 \pm 0.13$ $1.09 \pm 0.13$ $0.534$ Methionine adenosyltransferase1 (mat1) $1.00 \pm 0.15$ $0.70 \pm 0.15$ $1.10 \pm 0.13$ $0.271$ Growth hormone receptor (ghr) $1.00 \pm 0.20$ $0.74 \pm 0.45$ $0.94 \pm 0.17$ $0.640$ Interleukin 8 (il/8) $1.00 \pm 0.20$ $1.10 \pm 0.17$ $1.4 \pm 0.12$ $0.663$ <b>PROTEIN TURNOVER (Muscle)</b> Indeplagy-related protein 4 homolog B (atg4b) $1.00 \pm 0.09$ $1.28 \pm 0.20$ $1.24 \pm 0.11$ $0.401$ Autophagy-related protein 1a (murf1a) $1.00 \pm 0.09^b$ $1.04 \pm 0.05^{ab}$		$0.26^{ab}$							
Fatty acyl elongase 6 (elovl6) $1.00 \pm 0.50$ $1.17 \pm 0.78$ $0.91 \pm 0.39$ $0.577$ Delta-6 fatty acyl desaturase isoform a (fads2d6a) $1.00 \pm 0.34^{a}$ $0.36 \pm 0.09^{b}$ $0.44 \pm$ $0.035$ S-acyl fatty acid synthase thioesterase (fas) $1.00 \pm 0.14$ $0.90 \pm 0.09$ $1.00 \pm 0.10$ $0.671$ <b>1-CARBON METABOLISM (Liver)</b> $0.90 \pm 0.09$ $1.00 \pm 0.10$ $0.671$ Cystathionine- $\beta$ -synthase (cbs) $1.00 \pm 0.26$ $0.91 \pm 0.31$ $0.86 \pm 0.26$ $0.854$ Betaine-homocysteine S-methyltransferase (bhmt) $1.00 \pm 0.13$ $0.91 \pm 0.13$ $0.534$ Methionine adenosyltransferase1 (mat1) $1.00 \pm 0.15$ $0.70 \pm 0.15$ $1.10 \pm 0.13$ $0.271$ Growth hormone receptor (ghr) $1.00 \pm 0.20$ $0.74 \pm 0.45$ $0.94 \pm 0.17$ $0.640$ Interleukin 8 (il8) $1.00 \pm 0.20$ $0.74 \pm 0.45$ $0.94 \pm 0.17$ $0.640$ Interleukin 1 beta (il1b) $1.00 \pm 0.09$ $1.28 \pm 0.20$ $1.24 \pm 0.11$ $0.401$ Autophagy-related protein 4 homolog B (atg4b) $1.00 \pm 0.09$ $1.24 \pm 0.06^{ab}$ $1.47 \pm 0.09^{a}$ $0.029$ GABA(A) receptor-associated protein (gabarap) $1.00 \pm 0.09^{b$	Fatty acyl elongase 5 isoform b (elov15)	$1.00\pm0.07$	$1.07 \pm 0.14$	$0.84 \pm 0.16$	0.454				
Delta-6 fatty acyl desaturase isoform a (fads2d6a) $1.00 \pm 0.34^a$ $0.36 \pm 0.09^b$ $0.44 \pm 0.035$ S-acyl fatty acid synthase thioesterase (fas) $1.00 \pm 0.14$ $0.90 \pm 0.09$ $1.00 \pm 0.10$ $0.671$ I-CARBON METABOLISM (Liver) $0.00 \pm 0.14$ $0.90 \pm 0.09$ $1.00 \pm 0.10$ $0.671$ Cystathionine-fl-synthase (cbs) $1.00 \pm 0.26$ $0.91 \pm 0.31$ $0.86 \pm 0.26$ $0.854$ Betaine-homocysteine S-methyltransferase (bhmt) $1.00 \pm 0.13$ $0.91 \pm 0.13$ $1.09 \pm 0.13$ $0.534$ Methionine adenosyltransferase (mat1) $1.00 \pm 0.13$ $0.91 \pm 0.13$ $1.09 \pm 0.13$ $0.534$ Growth hormone receptor (ghr) $1.00 \pm 0.40^a$ $0.36 \pm 0.11^b$ $0.79 \pm 0.043$ Interleukin 8 (il8) $1.00 \pm 0.20$ $0.74 \pm 0.45$ $0.94 \pm 0.17$ $0.640$ Interleukin 1 beta (il1b) $1.00 \pm 0.20$ $1.10 \pm 0.17$ $1.14 \pm 0.12$ $0.663$ PROTEIN TURNOVER (Muscle) $1.00 \pm 0.09$ $1.28 \pm 0.20$ $1.24 \pm 0.11$ $0.401$ Autophagy-related protein 4 homolog B (atg4b) $1.00 \pm 0.09^b$ $1.24 \pm 0.06^{ab}$ $1.47 \pm 0.09^a$ $0.029$ $0.44 \pm 0.12^a$ $0.004^a$ $0.029^{ab}$	Fatty acyl elongase 6 (elovl6)	$1.00 \pm 0.50$	$1.17 \pm 0.78$	$0.91 \pm 0.39$	0.577				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Delta-6 fatty acyl desaturase isoform a (fads2d6a)	$1.00 \pm 0.34^{a}$	$0.36\pm0.09^{\text{b}}$	$0.44 \pm$	0.035				
S-acyl fatty acid synthase thioesterase (fas) $1.00 \pm 0.14$ $0.90 \pm 0.09$ $1.00 \pm 0.10$ $0.671$ I-CARBON METABOLISM (Liver) $0.00 \pm 0.26$ $0.91 \pm 0.31$ $0.86 \pm 0.26$ $0.854$ Betaine-homocysteine S-methyltransferase (bhmt) $1.00 \pm 0.13$ $0.91 \pm 0.13$ $1.09 \pm 0.13$ $0.534$ Methionine adenosyltransferase1 (mat1) $1.00 \pm 0.15$ $0.70 \pm 0.15$ $1.10 \pm 0.13$ $0.271$ Growth hormone receptor (ghr) $1.00 \pm 0.40^a$ $0.36 \pm 0.11^b$ $0.79 \pm$ $0.043$ IMMUNE FUNCTION (Liver)       Interleukin 8 (il8) $1.00 \pm 0.20$ $0.74 \pm 0.45$ $0.94 \pm 0.17$ $0.640$ Interleukin 1 beta (il1b) $1.00 \pm 0.20$ $0.74 \pm 0.45$ $0.94 \pm 0.17$ $0.640$ Mutophagy-related protein 4 homolog B (atg4b) $1.00 \pm 0.20$ $1.10 \pm 0.17$ $1.14 \pm 0.12$ $0.663$ PROTEIN TURNOVER (Muscle)       I.00 \pm 0.09 $1.28 \pm 0.20$ $1.24 \pm 0.11$ $0.401$ Autophagy-related protein 4 homolog B (atg4b) $1.00 \pm 0.05^b$ $1.24 \pm 0.06^{ab}$ $1.47 \pm 0.09^a$ $0.029$ GABA(A) receptor-associated protein $(gabarap)$ $1.00 \pm 0.04^b$ $1.11 \pm 0.17^{ab}$ $1.19 \pm 0.08^a$ $0.049$				$0.12^{ab}$					
1-CARBON METABOLISM (Liver)         Cystathionine- $\beta$ -synthase (cbs) $1.00 \pm 0.26$ $0.91 \pm 0.31$ $0.86 \pm 0.26$ $0.854$ Betaine-homocysteine S-methyltransferase (bhmt) $1.00 \pm 0.13$ $0.91 \pm 0.13$ $1.09 \pm 0.13$ $0.534$ Methionine adenosyltransferase1 (mat1) $1.00 \pm 0.15$ $0.70 \pm 0.15$ $1.10 \pm 0.13$ $0.271$ Growth hormone receptor (ghr) $1.00 \pm 0.40^a$ $0.36 \pm 0.11^b$ $0.79 \pm 0.043$ $0.32^{ab}$ IMMUNE FUNCTION (Liver)       Interleukin 8 (il8) $1.00 \pm 0.20$ $0.74 \pm 0.45$ $0.94 \pm 0.17$ $0.640$ Interleukin 1 beta (il1b) $1.00 \pm 0.20$ $1.10 \pm 0.17$ $1.14 \pm 0.12$ $0.663$ PROTEIN TURNOVER (Muscle)       Interleukin 1 beta (il1b) $1.00 \pm 0.09$ $1.28 \pm 0.20$ $1.24 \pm 0.11$ $0.401$ Autophagy-related protein 4 homolog B (atg4b) $1.00 \pm 0.09^{b}$ $1.24 \pm 0.06^{ab}$ $1.29 \pm 0.09^{a}$ $0.029$ GABA(A) receptor-associated protein (gabarap) $1.00 \pm 0.05^{b}$ $1.24 \pm 0.06^{ab}$ $1.47 \pm 0.09^{a}$ $0.001$ Muscle-specific RING finger protein 1a (murf1a) $1.00 \pm 0.09^{b}$ $1.20 \pm 0.09^{ab}$ $1.48 \pm 0.07^{a}$ $0.002$ Muscle-spe	S-acyl fatty acid synthase thioesterase (fas)	$1.00\pm0.14$	$0.90\pm0.09$	$1.00\pm0.10$	0.671				
Cystathionine- $\beta$ -synthase (cbs) $1.00 \pm 0.26$ $0.91 \pm 0.31$ $0.86 \pm 0.26$ $0.854$ Betaine-homocysteine S-methyltransferase (bhmt) $1.00 \pm 0.13$ $0.91 \pm 0.13$ $1.09 \pm 0.13$ $0.534$ Methionine adenosyltransferase1 (mat1) $1.00 \pm 0.15$ $0.70 \pm 0.15$ $1.10 \pm 0.13$ $0.271$ Growth hormone receptor (ghr) $1.00 \pm 0.40^a$ $0.36 \pm 0.11^b$ $0.79 \pm 0.043$ IMMUNE FUNCTION (Liver) $0.00 \pm 0.20$ $0.74 \pm 0.45$ $0.94 \pm 0.17$ $0.640$ Interleukin 8 (il8) $1.00 \pm 0.20$ $0.74 \pm 0.45$ $0.94 \pm 0.17$ $0.640$ Interleukin 1 beta (il1b) $1.00 \pm 0.20$ $1.10 \pm 0.17$ $1.14 \pm 0.12$ $0.663$ PROTEIN TURNOVER (Muscle) $1.00 \pm 0.09$ $1.28 \pm 0.20$ $1.24 \pm 0.11$ $0.401$ Autophagy-related protein 4 homolog B (atg4b) $1.00 \pm 0.09^b$ $1.04 \pm 0.05^{ab}$ $1.29 \pm 0.09^a$ $0.029^a$ GABA(A) receptor-associated protein (gabarap) $1.00 \pm 0.09^b$ $1.24 \pm 0.06^{ab}$ $1.47 \pm 0.09^a$ $0.049^a$ Muscle-specific RING finger protein 1a (murf1a) $1.00 \pm 0.09^b$ $1.20 \pm 0.09^{ab}$ $1.48 \pm 0.07^a$ $0.002$ Microtubule-associated proteins 1A/1B light chain 3B precursor (mlp3b) $0.02 \pm 0.12$ $0.73 \pm 0.16$ $0.98 \pm 0.15$ $0.427$	1-CARBON METABOLISM (Liver)								
Betaine-homocysteine S-methyltransferase ( <i>bhmt</i> ) $1.00 \pm 0.13$ $0.91 \pm 0.13$ $1.09 \pm 0.13$ $0.534$ Methionine adenosyltransferase1 ( <i>mat1</i> ) $1.00 \pm 0.15$ $0.70 \pm 0.15$ $1.10 \pm 0.13$ $0.271$ Growth hormone receptor ( <i>ghr</i> ) $1.00 \pm 0.40^a$ $0.36 \pm 0.11^b$ $0.79 \pm 0.043$ IMMUNE FUNCTION (Liver) $0.00 \pm 0.40^a$ $0.36 \pm 0.11^b$ $0.79 \pm 0.043$ Interleukin 8 ( <i>il8</i> ) $1.00 \pm 0.20$ $0.74 \pm 0.45$ $0.94 \pm 0.17$ $0.640$ Interleukin 1 beta ( <i>il1b</i> ) $1.00 \pm 0.20$ $1.10 \pm 0.17$ $1.14 \pm 0.12$ $0.663$ PROTEIN TURNOVER (Muscle) $1.00 \pm 0.09$ $1.28 \pm 0.20$ $1.24 \pm 0.11$ $0.401$ Autophagy-related protein 4 homolog B ( <i>atg4b</i> ) $1.00 \pm 0.09$ $1.28 \pm 0.20$ $1.24 \pm 0.11$ $0.401$ Muscle-specific RING finger protein 1a ( <i>murf1a</i> ) $1.00 \pm 0.09^b$ $1.24 \pm 0.06^{ab}$ $1.47 \pm 0.09^a$ $0.002$ Muscle-specific RING finger protein 1b ( <i>murf1b</i> ) $1.00 \pm 0.09^b$ $1.01 \pm 0.18$ $1.51 \pm 0.25$ $0.057$ Microtubule-associated proteins 1A/1B light chain $1.00 \pm 0.06^b$ $1.20 \pm 0.09^{ab}$ $1.48 \pm 0.07^a$ $0.002$ GROWTH & GLUCOSE TRANSPORT (Muscle) $0.73 \pm 0.16$ $0.98 \pm 0.15$ $0.427$	Cystathionine- $\beta$ -synthase ( <i>cbs</i> )	$1.00\pm0.26$	$0.91\pm0.31$	$0.86\pm0.26$	0.854				
Methionine adenosyltransferase1 (mat1) $1.00 \pm 0.15$ $0.70 \pm 0.15$ $1.10 \pm 0.13$ $0.271$ Growth hormone receptor (ghr) $1.00 \pm 0.40^a$ $0.36 \pm 0.11^b$ $0.79 \pm 0.043$ $0.32^{ab}$ $0.32^{ab}$ IMMUNE FUNCTION (Liver)Interleukin 8 (il8) $1.00 \pm 0.20$ $0.74 \pm 0.45$ $0.94 \pm 0.17$ $0.640$ Interleukin 1 beta (il1b) $1.00 \pm 0.20$ $1.10 \pm 0.17$ $1.14 \pm 0.12$ $0.663$ PROTEIN TURNOVER (Muscle)Autophagy-related protein 4 homolog B (atg4b) $1.00 \pm 0.09$ $1.28 \pm 0.20$ $1.24 \pm 0.11$ $0.401$ Autophagy related 12 (atg12) $1.00 \pm 0.09^b$ $1.24 \pm 0.06^{ab}$ $1.29 \pm 0.09^a$ $0.029$ GABA(A) receptor-associated protein (gabarap) $1.00 \pm 0.04^b$ $1.11 \pm 0.17^{ab}$ $1.19 \pm 0.08^a$ $0.049$ Muscle-specific RING finger protein 1a (murf1a) $1.00 \pm 0.09^b$ $1.20 \pm 0.09^{ab}$ $1.48 \pm 0.07^a$ $0.002$ Microtubule-associated proteins 1A/1B light chain $1.00 \pm 0.06^b$ $1.20 \pm 0.09^{ab}$ $1.48 \pm 0.07^a$ $0.002$ B precursor (mlp3b)GROWTH & GLUCOSE TRANSPORT (Muscle) $0.73 \pm 0.16$ $0.98 \pm 0.15$ $0.427$	Betaine-homocysteine S-methyltransferase (bhmt)	$1.00\pm0.13$	$0.91\pm0.13$	$1.09\pm0.13$	0.534				
Growth hormone receptor (ghr) $1.00 \pm 0.40^a$ $0.36 \pm 0.11^b$ $0.79 \pm 0.043$ $0.32^{ab}$ IMMUNE FUNCTION (Liver)Interleukin 8 (il8) $1.00 \pm 0.20$ $0.74 \pm 0.45$ $0.94 \pm 0.17$ $0.640$ $0.663$ Interleukin 1 beta (il1b) $1.00 \pm 0.20$ $1.10 \pm 0.17$ $1.14 \pm 0.12$ $0.663$ PROTEIN TURNOVER (Muscle)Autophagy-related protein 4 homolog B (atg4b) $1.00 \pm 0.09$ $1.28 \pm 0.20$ $1.24 \pm 0.11$ $0.401$ Autophagy related 12 (atg12) $1.00 \pm 0.09^b$ $1.04 \pm 0.05^{ab}$ $1.29 \pm 0.09^a$ $0.029$ GABA(A) receptor-associated protein (gabarap) $1.00 \pm 0.04^b$ $1.11 \pm 0.17^{ab}$ $1.47 \pm 0.09^a$ $0.001$ Muscle-specific RING finger protein 1a (murf1a) $1.00 \pm 0.09^b$ $1.01 \pm 0.18$ $1.51 \pm 0.25$ $0.057$ Microtubule-associated proteins 1A/1B light chain 3B precursor (mlp3b) $1.00 \pm 0.12$ $0.73 \pm 0.16$ $0.98 \pm 0.15$ $0.427$	Methionine adenosyltransferase1 (mat1)	$1.00\pm0.15$	$0.70\pm0.15$	$1.10\pm0.13$	0.271				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Growth hormone receptor (ghr)	$1.00\pm0.40^{a}$	$0.36\pm0.11^{b}$	$0.79 \pm$	0.043				
IMMUNE FUNCTION (Liver)Interleukin 8 (il8) $1.00 \pm 0.20$ $0.74 \pm 0.45$ $0.94 \pm 0.17$ $0.640$ Interleukin 1 beta (il1b) $1.00 \pm 0.20$ $1.10 \pm 0.17$ $1.14 \pm 0.12$ $0.663$ PROTEIN TURNOVER (Muscle)Autophagy-related protein 4 homolog B (atg4b) $1.00 \pm 0.09$ $1.28 \pm 0.20$ $1.24 \pm 0.11$ $0.401$ Autophagy related 12 (atg12) $1.00 \pm 0.09^{\text{b}}$ $1.04 \pm 0.05^{\text{ab}}$ $1.29 \pm 0.09^{\text{a}}$ $0.029$ GABA(A) receptor-associated protein (gabarap) $1.00 \pm 0.05^{\text{b}}$ $1.24 \pm 0.06^{\text{ab}}$ $1.47 \pm 0.09^{\text{a}}$ $0.001$ Muscle-specific RING finger protein 1a (murf1a) $1.00 \pm 0.04^{\text{b}}$ $1.11 \pm 0.17^{\text{ab}}$ $1.19 \pm 0.08^{\text{a}}$ $0.049$ Muscle-specific RING finger protein 1b (murf1b) $1.00 \pm 0.09^{\text{b}}$ $1.20 \pm 0.09^{\text{ab}}$ $1.48 \pm 0.07^{\text{a}}$ $0.002$ B precursor (mlp3b) $1.00 \pm 0.12$ $0.73 \pm 0.16$ $0.98 \pm 0.15$ $0.427$				0.32 <sup>ab</sup>					
Interleukin 8 (il8) $1.00 \pm 0.20$ $0.74 \pm 0.45$ $0.94 \pm 0.17$ $0.640$ Interleukin 1 beta (il1b) $1.00 \pm 0.20$ $1.10 \pm 0.17$ $1.14 \pm 0.12$ $0.663$ <b>PROTEIN TURNOVER (Muscle)</b> Autophagy-related protein 4 homolog B (atg4b) $1.00 \pm 0.09$ $1.28 \pm 0.20$ $1.24 \pm 0.11$ $0.401$ Autophagy related 12 (atg12) $1.00 \pm 0.09$ $1.28 \pm 0.20$ $1.24 \pm 0.11$ $0.401$ Autophagy related 12 (atg12) $1.00 \pm 0.09^{b}$ $1.24 \pm 0.06^{ab}$ $1.47 \pm 0.09^{a}$ $0.029$ GABA(A) receptor-associated protein (gabarap) $1.00 \pm 0.05^{b}$ $1.24 \pm 0.06^{ab}$ $1.47 \pm 0.09^{a}$ $0.001$ Muscle-specific RING finger protein 1a (murf1a) $1.00 \pm 0.09^{b}$ $1.11 \pm 0.17^{ab}$ $1.19 \pm 0.08^{a}$ $0.049$ Muscle-specific RING finger protein 1b (murf1b) $1.00 \pm 0.09^{b}$ $1.20 \pm 0.09^{ab}$ $1.48 \pm 0.07^{a}$ $0.002$ B precursor (mlp3b) $1.00 \pm 0.12$ $0.73 \pm 0.16$ $0.98 \pm 0.15$ $0.427$	<b>IMMUNE FUNCTION (Liver)</b>								
Interleukin 1 beta ( <i>il1b</i> ) $1.00 \pm 0.20$ $1.10 \pm 0.17$ $1.14 \pm 0.12$ $0.663$ <b>PROTEIN TURNOVER (Muscle)</b> Autophagy-related protein 4 homolog B ( <i>atg4b</i> ) $1.00 \pm 0.09$ $1.28 \pm 0.20$ $1.24 \pm 0.11$ $0.401$ Autophagy related 12 ( <i>atg12</i> ) $1.00 \pm 0.08^{b}$ $1.04 \pm 0.05^{ab}$ $1.29 \pm 0.09^{a}$ $0.029$ GABA(A) receptor-associated protein ( <i>gabarap</i> ) $1.00 \pm 0.05^{b}$ $1.24 \pm 0.06^{ab}$ $1.47 \pm 0.09^{a}$ $0.001$ Muscle-specific RING finger protein 1a ( <i>murf1a</i> ) $1.00 \pm 0.04^{b}$ $1.11 \pm 0.17^{ab}$ $1.19 \pm 0.08^{a}$ $0.049$ Microtubule-associated proteins 1A/1B light chain $1.00 \pm 0.06^{b}$ $1.20 \pm 0.09^{ab}$ $1.48 \pm 0.07^{a}$ $0.002$ GROWTH & GLUCOSE TRANSPORT (Muscle) $1.00 \pm 0.12$ $0.73 \pm 0.16$ $0.98 \pm 0.15$ $0.427$	Interleukin 8 ( <i>il8</i> )	$1.00\pm0.20$	$0.74\pm0.45$	$0.94\pm0.17$	0.640				
PROTEIN TURNOVER (Muscle)Autophagy-related protein 4 homolog B (atg4b) $1.00 \pm 0.09$ $1.28 \pm 0.20$ $1.24 \pm 0.11$ $0.401$ Autophagy related 12 (atg12) $1.00 \pm 0.08^{b}$ $1.04 \pm 0.05^{ab}$ $1.29 \pm 0.09^{a}$ $0.029$ GABA(A) receptor-associated protein (gabarap) $1.00 \pm 0.05^{b}$ $1.24 \pm 0.06^{ab}$ $1.47 \pm 0.09^{a}$ $0.001$ Muscle-specific RING finger protein 1a (murf1a) $1.00 \pm 0.04^{b}$ $1.11 \pm 0.17^{ab}$ $1.19 \pm 0.08^{a}$ $0.049$ Muscle-specific RING finger protein 1b (murf1b) $1.00 \pm 0.09^{a}$ $1.01 \pm 0.18$ $1.51 \pm 0.25$ $0.057$ Microtubule-associated proteins 1A/1B light chain 3B precursor (mlp3b) $1.00 \pm 0.06^{b}$ $1.20 \pm 0.09^{ab}$ $1.48 \pm 0.07^{a}$ $0.002$ GROWTH & GLUCOSE TRANSPORT (Muscle) $1.00 \pm 0.12$ $0.73 \pm 0.16$ $0.98 \pm 0.15$ $0.427$	Interleukin 1 beta ( <i>il1b</i> )	$1.00\pm0.20$	$1.10\pm0.17$	$1.14\pm0.12$	0.663				
Autophagy-related protein 4 homolog B (atg4b) $1.00 \pm 0.09$ $1.28 \pm 0.20$ $1.24 \pm 0.11$ $0.401$ Autophagy related 12 (atg12) $1.00 \pm 0.08^{b}$ $1.04 \pm 0.05^{ab}$ $1.29 \pm 0.09^{a}$ $0.029$ GABA(A) receptor-associated protein (gabarap) $1.00 \pm 0.05^{b}$ $1.24 \pm 0.06^{ab}$ $1.47 \pm 0.09^{a}$ $0.001$ Muscle-specific RING finger protein 1a (murf1a) $1.00 \pm 0.04^{b}$ $1.11 \pm 0.17^{ab}$ $1.19 \pm 0.08^{a}$ $0.049$ Muscle-specific RING finger protein 1b (murf1b) $1.00 \pm 0.09^{a}$ $1.01 \pm 0.18$ $1.51 \pm 0.25$ $0.057$ Microtubule-associated proteins 1A/1B light chain $1.00 \pm 0.06^{b}$ $1.20 \pm 0.09^{ab}$ $1.48 \pm 0.07^{a}$ $0.002$ GROWTH & GLUCOSE TRANSPORT (Muscle) $0.00 \pm 0.12$ $0.73 \pm 0.16$ $0.98 \pm 0.15$ $0.427$	PROTEIN TURNOVER (Muscle)								
Autophagy related 12 (atg12) $1.00 \pm 0.08^{b}$ $1.04 \pm 0.05^{ab}$ $1.29 \pm 0.09^{a}$ $0.029$ GABA(A) receptor-associated protein (gabarap) $1.00 \pm 0.05^{b}$ $1.24 \pm 0.06^{ab}$ $1.47 \pm 0.09^{a}$ $0.001$ Muscle-specific RING finger protein 1a (murf1a) $1.00 \pm 0.04^{b}$ $1.11 \pm 0.17^{ab}$ $1.19 \pm 0.08^{a}$ $0.049$ Muscle-specific RING finger protein 1b (murf1b) $1.00 \pm 0.09^{a}$ $1.01 \pm 0.18$ $1.51 \pm 0.25$ $0.057$ Microtubule-associated proteins 1A/1B light chain $1.00 \pm 0.06^{b}$ $1.20 \pm 0.09^{ab}$ $1.48 \pm 0.07^{a}$ $0.002$ B precursor (mlp3b) $0.00 \pm 0.12$ $0.73 \pm 0.16$ $0.98 \pm 0.15$ $0.427$	Autophagy-related protein 4 homolog B (atg4b)	$1.00\pm0.09$	$1.28\pm0.20$	$1.24\pm0.11$	0.401				
GABA(A) receptor-associated protein (gabarap) $1.00 \pm 0.05^{b}$ $1.24 \pm 0.06^{ab}$ $1.47 \pm 0.09^{a}$ $0.001$ Muscle-specific RING finger protein 1a (murf1a) $1.00 \pm 0.04^{b}$ $1.11 \pm 0.17^{ab}$ $1.19 \pm 0.08^{a}$ $0.049$ Muscle-specific RING finger protein 1b (murf1b) $1.00 \pm 0.09$ $1.01 \pm 0.18$ $1.51 \pm 0.25$ $0.057$ Microtubule-associated proteins 1A/1B light chain $1.00 \pm 0.06^{b}$ $1.20 \pm 0.09^{ab}$ $1.48 \pm 0.07^{a}$ $0.002$ B precursor (mlp3b) $0.00 \pm 0.12$ $0.73 \pm 0.16$ $0.98 \pm 0.15$ $0.427$	Autophagy related 12 (atg12)	$1.00\pm0.08^{b}$	$1.04\pm0.05^{ab}$	$1.29\pm0.09^{a}$	0.029				
Muscle-specific RING finger protein 1a (murf1a) $1.00 \pm 0.04^{b}$ $1.11 \pm 0.17^{ab}$ $1.19 \pm 0.08^{a}$ $0.049$ Muscle-specific RING finger protein 1b (murf1b) $1.00 \pm 0.09$ $1.01 \pm 0.18$ $1.51 \pm 0.25$ $0.057$ Microtubule-associated proteins 1A/1B light chain $1.00 \pm 0.06^{b}$ $1.20 \pm 0.09^{ab}$ $1.48 \pm 0.07^{a}$ $0.002$ B precursor (mlp3b)       GROWTH & GLUCOSE TRANSPORT (Muscle) $0.73 \pm 0.16$ $0.98 \pm 0.15$ $0.427$	GABA(A) receptor-associated protein (gabarap)	$1.00\pm0.05^{\rm b}$	$1.24\pm0.06^{ab}$	$1.47 \pm 0.09^{a}$	0.001				
Muscle-specific RING finger protein 1b (murf1b) $1.00 \pm 0.09$ $1.01 \pm 0.18$ $1.51 \pm 0.25$ $0.057$ Microtubule-associated proteins 1A/1B light chain $1.00 \pm 0.06^{b}$ $1.20 \pm 0.09^{ab}$ $1.48 \pm 0.07^{a}$ $0.002$ B precursor (mlp3b)       GROWTH & GLUCOSE TRANSPORT (Muscle) $1.00 \pm 0.12$ $0.73 \pm 0.16$ $0.98 \pm 0.15$ $0.427$	Muscle-specific RING finger protein 1a (murf1a)	$1.00\pm0.04^{b}$	$1.11\pm0.17^{ab}$	$1.19\pm0.08^{a}$	0.049				
Microtubule-associated proteins 1A/1B light chain $1.00 \pm 0.06^{b}$ $1.20 \pm 0.09^{ab}$ $1.48 \pm 0.07^{a}$ $0.002$ 3B precursor (mlp3b)       GROWTH & GLUCOSE TRANSPORT (Muscle)         GROWTH & GLUCOSE TRANSPORT (Muscle)         Growth hormone receptor (ghr) $1.00 \pm 0.12$ $0.73 \pm 0.16$ $0.98 \pm 0.15$ $0.427$	Muscle-specific RING finger protein 1b (murf1b)	$1.00\pm0.09$	$1.01\pm0.18$	$1.51\pm0.25$	0.057				
GROWTH & GLUCOSE TRANSPORT (Muscle)Growth hormone receptor (ghr) $1.00 \pm 0.12$ $0.73 \pm 0.16$ $0.98 \pm 0.15$ $0.427$	Microtubule-associated proteins 1A/1B light chain 3B procursor (mln3b)	$1.00\pm0.06^{b}$	$1.20\pm0.09^{ab}$	$1.48\pm0.07^{\rm a}$	0.002				
Growth hormone receptor (ghr) $1.00 \pm 0.12$ $0.73 \pm 0.16$ $0.98 \pm 0.15$ $0.427$	CROWTH & CLUCOSE TRANSPORT (Muscle)								
$1.00 \pm 0.12$ $0.75 \pm 0.10$ $0.90 \pm 0.15$ $0.427$	Growth hormone receptor ( <i>ghr</i> )	$\frac{100+0.12}{1.00+0.12}$	$0.73 \pm 0.16$	$0.98 \pm 0.15$	0.427				
<b>Insulin-like growth factor 1</b> ( <i>igf1</i> ) $100 + 027 = 117 + 033 = 143 + 038 = 0251$	Insulin-like growth factor 1 ( <i>igf1</i> )	$1.00 \pm 0.12$ $1.00 \pm 0.27$	$1.17 \pm 0.10$	$1.43 \pm 0.13$	0.727 0.251				
Glucose transporter type 4 (glut4) $1.00 \pm 0.27$ $1.17 \pm 0.55$ $1.45 \pm 0.50$ $0.251$	Glucose transporter type 4 ( <i>glut4</i> )	$1.00 \pm 0.27$ $1.00 \pm 0.06$	$0.95 \pm 0.03$	0.98 + 0.00	0.231 0.824				
IMMUNE FUNCTION (Muscle)									
Interleukin 1 beta ( <i>il1b</i> ) $1.00 \pm 0.33$ $1.04 \pm 0.64$ $0.80 \pm 0.11$ $0.488$	Interleukin 1 beta ( <i>il1b</i> )	$1.00 \pm 0.33$	$1.04 \pm 0.64$	0.80 ± 0.11	0.488				

1088 Fig.1.



Fig. 2.



# Fig 3.

Α

В



Signal transduction and signaling molecules 15%

9%

# Fig 4.







В



- Steroid biosynthesis [PATH:ko00100] Sphingolipid metabolism [PATH:ko00600]
  - Purine metabolism [PATH:ko00230]
- Pyrimidine metabolism [PATH:ko00240] ·
- Oxidative phosphorylation [PATH:ko00190]
- Terpenoid backbone biosynthesis [PATH:ko00900] -
- Glycine, serine and threonine metabolism [PATH:ko00260]
  - Lysine degradation [PATH:ko00310]
  - Glutathione metabolism [PATH:ko00480]
- Glyoxylate and dicarboxylate metabolism [PATH:ko00630]
  - Glycolysis / Gluconeogenesis [PATH:ko00010]